WO2017125765A1 - Immunotherapeutic treatment of cancer - Google Patents
Immunotherapeutic treatment of cancer Download PDFInfo
- Publication number
- WO2017125765A1 WO2017125765A1 PCT/GB2017/050164 GB2017050164W WO2017125765A1 WO 2017125765 A1 WO2017125765 A1 WO 2017125765A1 GB 2017050164 W GB2017050164 W GB 2017050164W WO 2017125765 A1 WO2017125765 A1 WO 2017125765A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- mycobacterium
- preparation
- cancer
- tumour
- taa
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 166
- 238000011282 treatment Methods 0.000 title claims abstract description 19
- 201000011510 cancer Diseases 0.000 title abstract description 62
- 230000001024 immunotherapeutic effect Effects 0.000 title description 6
- 241000186359 Mycobacterium Species 0.000 claims abstract description 67
- 239000000427 antigen Substances 0.000 claims abstract description 46
- 108091007433 antigens Proteins 0.000 claims abstract description 46
- 102000036639 antigens Human genes 0.000 claims abstract description 45
- 238000002360 preparation method Methods 0.000 claims abstract description 26
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 51
- 210000004027 cell Anatomy 0.000 claims description 48
- 229960005545 IMM-101 Drugs 0.000 claims description 37
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 claims description 29
- 230000001613 neoplastic effect Effects 0.000 claims description 28
- 102000013701 Cyclin-Dependent Kinase 4 Human genes 0.000 claims description 26
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 claims description 26
- -1 RASK Proteins 0.000 claims description 26
- 241000187918 Mycobacterium obuense Species 0.000 claims description 24
- 201000010099 disease Diseases 0.000 claims description 24
- 238000000034 method Methods 0.000 claims description 19
- 101150108242 CDC27 gene Proteins 0.000 claims description 18
- 230000001225 therapeutic effect Effects 0.000 claims description 18
- 102000052587 Anaphase-Promoting Complex-Cyclosome Apc3 Subunit Human genes 0.000 claims description 17
- 108700004606 Anaphase-Promoting Complex-Cyclosome Apc3 Subunit Proteins 0.000 claims description 17
- 101100216227 Dictyostelium discoideum anapc3 gene Proteins 0.000 claims description 17
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 16
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 16
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 claims description 15
- 210000004443 dendritic cell Anatomy 0.000 claims description 14
- 102100039361 Chondrosarcoma-associated gene 2/3 protein Human genes 0.000 claims description 13
- 101000745414 Homo sapiens Chondrosarcoma-associated gene 2/3 protein Proteins 0.000 claims description 13
- 101001005728 Homo sapiens Melanoma-associated antigen 1 Proteins 0.000 claims description 13
- 101000814315 Homo sapiens Wilms tumor protein 1-interacting protein Proteins 0.000 claims description 13
- 102100025050 Melanoma-associated antigen 1 Human genes 0.000 claims description 13
- 102100039456 Wilms tumor protein 1-interacting protein Human genes 0.000 claims description 13
- 241000187644 Mycobacterium vaccae Species 0.000 claims description 12
- 230000037452 priming Effects 0.000 claims description 8
- 102100040578 G antigen 7 Human genes 0.000 claims description 6
- 101000893968 Homo sapiens G antigen 7 Proteins 0.000 claims description 6
- 101000576802 Homo sapiens Mesothelin Proteins 0.000 claims description 6
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 claims description 6
- 101000880770 Homo sapiens Protein SSX2 Proteins 0.000 claims description 6
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims description 6
- 102100025096 Mesothelin Human genes 0.000 claims description 6
- 102100023123 Mucin-16 Human genes 0.000 claims description 6
- 102100037686 Protein SSX2 Human genes 0.000 claims description 6
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims description 6
- 230000002068 genetic effect Effects 0.000 claims description 5
- 238000002347 injection Methods 0.000 claims description 5
- 239000007924 injection Substances 0.000 claims description 5
- 238000007920 subcutaneous administration Methods 0.000 claims description 3
- 230000002601 intratumoral effect Effects 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 230000002685 pulmonary effect Effects 0.000 claims description 2
- 101000972282 Homo sapiens Mucin-5AC Proteins 0.000 claims 4
- 102100022496 Mucin-5AC Human genes 0.000 claims 4
- 239000003814 drug Substances 0.000 abstract description 5
- 108090000623 proteins and genes Proteins 0.000 description 30
- 230000003211 malignant effect Effects 0.000 description 29
- 102000004169 proteins and genes Human genes 0.000 description 22
- 208000035475 disorder Diseases 0.000 description 21
- 210000001744 T-lymphocyte Anatomy 0.000 description 19
- 230000004083 survival effect Effects 0.000 description 18
- 201000001441 melanoma Diseases 0.000 description 16
- 206010027476 Metastases Diseases 0.000 description 15
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 14
- 201000009030 Carcinoma Diseases 0.000 description 12
- 108010034536 Mucin 5AC Proteins 0.000 description 11
- 238000002869 basic local alignment search tool Methods 0.000 description 11
- 230000014509 gene expression Effects 0.000 description 11
- 230000028993 immune response Effects 0.000 description 11
- 230000009401 metastasis Effects 0.000 description 11
- 238000002560 therapeutic procedure Methods 0.000 description 11
- 102000009616 Mucin 5AC Human genes 0.000 description 10
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 10
- 230000004913 activation Effects 0.000 description 10
- 208000009956 adenocarcinoma Diseases 0.000 description 10
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 10
- 238000009169 immunotherapy Methods 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 10
- 241000186427 Cutibacterium acnes Species 0.000 description 9
- 101150029707 ERBB2 gene Proteins 0.000 description 9
- 208000026310 Breast neoplasm Diseases 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 230000001965 increasing effect Effects 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 8
- 206010061289 metastatic neoplasm Diseases 0.000 description 8
- 201000002528 pancreatic cancer Diseases 0.000 description 8
- 208000008443 pancreatic carcinoma Diseases 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- 206010006187 Breast cancer Diseases 0.000 description 7
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 7
- 206010025323 Lymphomas Diseases 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 210000000987 immune system Anatomy 0.000 description 7
- 210000001165 lymph node Anatomy 0.000 description 7
- 230000001394 metastastic effect Effects 0.000 description 7
- 230000009826 neoplastic cell growth Effects 0.000 description 7
- 230000035755 proliferation Effects 0.000 description 7
- 210000004881 tumor cell Anatomy 0.000 description 7
- 108090000695 Cytokines Proteins 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 6
- 206010039491 Sarcoma Diseases 0.000 description 6
- 210000001185 bone marrow Anatomy 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 6
- 229960005277 gemcitabine Drugs 0.000 description 6
- 208000032839 leukemia Diseases 0.000 description 6
- 230000035772 mutation Effects 0.000 description 6
- 230000001603 reducing effect Effects 0.000 description 6
- 230000008685 targeting Effects 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 229960005486 vaccine Drugs 0.000 description 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 5
- 206010033128 Ovarian cancer Diseases 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 4
- 206010009944 Colon cancer Diseases 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 4
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 108091000080 Phosphotransferase Proteins 0.000 description 4
- 206010060862 Prostate cancer Diseases 0.000 description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 239000012228 culture supernatant Substances 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 201000005202 lung cancer Diseases 0.000 description 4
- 208000020816 lung neoplasm Diseases 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 102000020233 phosphotransferase Human genes 0.000 description 4
- 210000001550 testis Anatomy 0.000 description 4
- 102000005446 Anaphase-Promoting Complex-Cyclosome Human genes 0.000 description 3
- 108010031677 Anaphase-Promoting Complex-Cyclosome Proteins 0.000 description 3
- 206010003571 Astrocytoma Diseases 0.000 description 3
- 208000005243 Chondrosarcoma Diseases 0.000 description 3
- 102000016736 Cyclin Human genes 0.000 description 3
- 108050006400 Cyclin Proteins 0.000 description 3
- 101710113436 GTPase KRas Proteins 0.000 description 3
- 206010018338 Glioma Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 102000015728 Mucins Human genes 0.000 description 3
- 108010063954 Mucins Proteins 0.000 description 3
- 108700020796 Oncogene Proteins 0.000 description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 230000005867 T cell response Effects 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 238000009566 cancer vaccine Methods 0.000 description 3
- 229940022399 cancer vaccine Drugs 0.000 description 3
- 230000001461 cytolytic effect Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 206010017758 gastric cancer Diseases 0.000 description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000002611 ovarian Effects 0.000 description 3
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 230000006641 stabilisation Effects 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 description 2
- 101150108519 CDK4 gene Proteins 0.000 description 2
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 2
- 102100033270 Cyclin-dependent kinase inhibitor 1 Human genes 0.000 description 2
- 102100024458 Cyclin-dependent kinase inhibitor 2A Human genes 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 230000004544 DNA amplification Effects 0.000 description 2
- 201000008808 Fibrosarcoma Diseases 0.000 description 2
- 102100030708 GTPase KRas Human genes 0.000 description 2
- 208000032612 Glial tumor Diseases 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 description 2
- 101000633054 Homo sapiens Zinc finger protein SNAI2 Proteins 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 102000043129 MHC class I family Human genes 0.000 description 2
- 108091054437 MHC class I family Proteins 0.000 description 2
- 102000043131 MHC class II family Human genes 0.000 description 2
- 108091054438 MHC class II family Proteins 0.000 description 2
- 206010027145 Melanocytic naevus Diseases 0.000 description 2
- 206010027406 Mesothelioma Diseases 0.000 description 2
- 108700011259 MicroRNAs Proteins 0.000 description 2
- 102100034256 Mucin-1 Human genes 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 241000187473 Mycobacterium aurum Species 0.000 description 2
- 241000187486 Mycobacterium flavescens Species 0.000 description 2
- 241001532512 Mycobacterium parafortuitum Species 0.000 description 2
- 241000187481 Mycobacterium phlei Species 0.000 description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
- 201000010133 Oligodendroglioma Diseases 0.000 description 2
- 108010058846 Ovalbumin Proteins 0.000 description 2
- 206010061332 Paraganglion neoplasm Diseases 0.000 description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 description 2
- 201000000582 Retinoblastoma Diseases 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- 208000008383 Wilms tumor Diseases 0.000 description 2
- 102100029570 Zinc finger protein SNAI2 Human genes 0.000 description 2
- 230000002707 ameloblastic effect Effects 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 201000000053 blastoma Diseases 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 201000008275 breast carcinoma Diseases 0.000 description 2
- 208000035269 cancer or benign tumor Diseases 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 208000009060 clear cell adenocarcinoma Diseases 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 201000008184 embryoma Diseases 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 208000010749 gastric carcinoma Diseases 0.000 description 2
- 238000011223 gene expression profiling Methods 0.000 description 2
- 230000030279 gene silencing Effects 0.000 description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 239000002679 microRNA Substances 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 201000008026 nephroblastoma Diseases 0.000 description 2
- 238000010899 nucleation Methods 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 229940092253 ovalbumin Drugs 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 210000004923 pancreatic tissue Anatomy 0.000 description 2
- 208000007312 paraganglioma Diseases 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 108010014186 ras Proteins Proteins 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 201000000498 stomach carcinoma Diseases 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 206010044412 transitional cell carcinoma Diseases 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 210000003932 urinary bladder Anatomy 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- SSOORFWOBGFTHL-OTEJMHTDSA-N (4S)-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-5-carbamimidamido-1-[[(2S)-5-carbamimidamido-1-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-[[(2S)-2-[[(2S)-2-[[(2S)-2,6-diaminohexanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-5-oxopentanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O SSOORFWOBGFTHL-OTEJMHTDSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 208000016557 Acute basophilic leukemia Diseases 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- 208000036832 Adenocarcinoma of ovary Diseases 0.000 description 1
- 208000004804 Adenomatous Polyps Diseases 0.000 description 1
- 208000012791 Alpha-heavy chain disease Diseases 0.000 description 1
- 201000003076 Angiosarcoma Diseases 0.000 description 1
- 101710145634 Antigen 1 Proteins 0.000 description 1
- 206010065869 Astrocytoma, low grade Diseases 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 208000035821 Benign schwannoma Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010073258 Brenner tumour Diseases 0.000 description 1
- 208000003170 Bronchiolo-Alveolar Adenocarcinoma Diseases 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 102100035793 CD83 antigen Human genes 0.000 description 1
- 102000000905 Cadherin Human genes 0.000 description 1
- 108050007957 Cadherin Proteins 0.000 description 1
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 description 1
- 102000004631 Calcineurin Human genes 0.000 description 1
- 108010042955 Calcineurin Proteins 0.000 description 1
- 101710167800 Capsid assembly scaffolding protein Proteins 0.000 description 1
- 206010007275 Carcinoid tumour Diseases 0.000 description 1
- 208000009458 Carcinoma in Situ Diseases 0.000 description 1
- 201000000274 Carcinosarcoma Diseases 0.000 description 1
- 101710109611 Cell division cycle protein 20 homolog Proteins 0.000 description 1
- 102100038099 Cell division cycle protein 20 homolog Human genes 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 206010008583 Chloroma Diseases 0.000 description 1
- 101710126325 Chondrosarcoma-associated gene 2/3 protein Proteins 0.000 description 1
- 201000009047 Chordoma Diseases 0.000 description 1
- 208000006332 Choriocarcinoma Diseases 0.000 description 1
- 108010058546 Cyclin D1 Proteins 0.000 description 1
- 108010009392 Cyclin-Dependent Kinase Inhibitor p16 Proteins 0.000 description 1
- 108010016788 Cyclin-Dependent Kinase Inhibitor p21 Proteins 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 102100033587 DNA topoisomerase 2-alpha Human genes 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 208000037162 Ductal Breast Carcinoma Diseases 0.000 description 1
- 208000007033 Dysgerminoma Diseases 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 201000009051 Embryonal Carcinoma Diseases 0.000 description 1
- 206010014958 Eosinophilic leukaemia Diseases 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- 208000031637 Erythroblastic Acute Leukemia Diseases 0.000 description 1
- 208000036566 Erythroleukaemia Diseases 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 201000006107 Familial adenomatous polyposis Diseases 0.000 description 1
- 206010053717 Fibrous histiocytoma Diseases 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 208000004463 Follicular Adenocarcinoma Diseases 0.000 description 1
- 102100024165 G1/S-specific cyclin-D1 Human genes 0.000 description 1
- 206010017708 Ganglioneuroblastoma Diseases 0.000 description 1
- 208000008999 Giant Cell Carcinoma Diseases 0.000 description 1
- 206010060980 Granular cell tumour Diseases 0.000 description 1
- 108010013476 HLA-A24 Antigen Proteins 0.000 description 1
- 208000002125 Hemangioendothelioma Diseases 0.000 description 1
- 208000006050 Hemangiopericytoma Diseases 0.000 description 1
- 208000001258 Hemangiosarcoma Diseases 0.000 description 1
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 1
- 208000002291 Histiocytic Sarcoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101100005713 Homo sapiens CD4 gene Proteins 0.000 description 1
- 101000946856 Homo sapiens CD83 antigen Proteins 0.000 description 1
- 101001046870 Homo sapiens Hypoxia-inducible factor 1-alpha Proteins 0.000 description 1
- 101000794228 Homo sapiens Mitotic checkpoint serine/threonine-protein kinase BUB1 beta Proteins 0.000 description 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
- 101000972278 Homo sapiens Mucin-6 Proteins 0.000 description 1
- 101000745415 Homo sapiens Putative chondrosarcoma-associated gene 1 protein Proteins 0.000 description 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
- 101000775102 Homo sapiens Transcriptional coactivator YAP1 Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 206010048643 Hypereosinophilic syndrome Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 102100022875 Hypoxia-inducible factor 1-alpha Human genes 0.000 description 1
- 208000007866 Immunoproliferative Small Intestinal Disease Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 102000014158 Interleukin-12 Subunit p40 Human genes 0.000 description 1
- 108010011429 Interleukin-12 Subunit p40 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 201000008869 Juxtacortical Osteosarcoma Diseases 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 125000002842 L-seryl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])O[H] 0.000 description 1
- 208000018142 Leiomyosarcoma Diseases 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 206010024305 Leukaemia monocytic Diseases 0.000 description 1
- 208000000265 Lobular Carcinoma Diseases 0.000 description 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
- 208000035771 Malignant Sertoli-Leydig cell tumor of the ovary Diseases 0.000 description 1
- 206010025538 Malignant ascites Diseases 0.000 description 1
- 229920000057 Mannan Polymers 0.000 description 1
- 102100025169 Max-binding protein MNT Human genes 0.000 description 1
- 208000007054 Medullary Carcinoma Diseases 0.000 description 1
- 208000002030 Merkel cell carcinoma Diseases 0.000 description 1
- 201000009574 Mesenchymal Chondrosarcoma Diseases 0.000 description 1
- 241000983409 Microbacterium terrae Species 0.000 description 1
- 108090000744 Mitogen-Activated Protein Kinase Kinases Proteins 0.000 description 1
- 102000004232 Mitogen-Activated Protein Kinase Kinases Human genes 0.000 description 1
- 102100030144 Mitotic checkpoint serine/threonine-protein kinase BUB1 beta Human genes 0.000 description 1
- 241001183012 Modified Vaccinia Ankara virus Species 0.000 description 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
- 206010057269 Mucoepidermoid carcinoma Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 108010085220 Multiprotein Complexes Proteins 0.000 description 1
- 102000007474 Multiprotein Complexes Human genes 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 241001467553 Mycobacterium africanum Species 0.000 description 1
- 241000187475 Mycobacterium aichiense Species 0.000 description 1
- 241000186367 Mycobacterium avium Species 0.000 description 1
- 241000187482 Mycobacterium avium subsp. paratuberculosis Species 0.000 description 1
- 241000187478 Mycobacterium chelonae Species 0.000 description 1
- 241000187913 Mycobacterium chubuense Species 0.000 description 1
- 241000187912 Mycobacterium diernhoferi Species 0.000 description 1
- 241001532524 Mycobacterium duvalii Species 0.000 description 1
- 241000186365 Mycobacterium fortuitum Species 0.000 description 1
- 241000187485 Mycobacterium gastri Species 0.000 description 1
- 241000187484 Mycobacterium gordonae Species 0.000 description 1
- 241001494992 Mycobacterium indicus pranii Species 0.000 description 1
- 241000186364 Mycobacterium intracellulare Species 0.000 description 1
- 241000186363 Mycobacterium kansasii Species 0.000 description 1
- 241000187483 Mycobacterium komossense Species 0.000 description 1
- 241000186362 Mycobacterium leprae Species 0.000 description 1
- 241000908167 Mycobacterium lepraemurium Species 0.000 description 1
- 241000187492 Mycobacterium marinum Species 0.000 description 1
- 241000187919 Mycobacterium microti Species 0.000 description 1
- 241000187469 Mycobacterium neoaurum Species 0.000 description 1
- 241000187491 Mycobacterium nonchromogenicum Species 0.000 description 1
- 241000520094 Mycobacterium paraffinicum Species 0.000 description 1
- 241000168058 Mycobacterium peregrinum Species 0.000 description 1
- 241001509458 Mycobacterium rhodesiae Species 0.000 description 1
- 241000187490 Mycobacterium scrofulaceum Species 0.000 description 1
- 241000187489 Mycobacterium simiae Species 0.000 description 1
- 241000187480 Mycobacterium smegmatis Species 0.000 description 1
- 241000187497 Mycobacterium sphagni Species 0.000 description 1
- 241000187477 Mycobacterium thermoresistibile Species 0.000 description 1
- 241001532502 Mycobacterium tokaiense Species 0.000 description 1
- 241000187476 Mycobacterium triviale Species 0.000 description 1
- 241000187917 Mycobacterium ulcerans Species 0.000 description 1
- 241000187494 Mycobacterium xenopi Species 0.000 description 1
- 108010084333 N-palmitoyl-S-(2,3-bis(palmitoyloxy)propyl)cysteinyl-seryl-lysyl-lysyl-lysyl-lysine Proteins 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 101100241454 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) nuc-2 gene Proteins 0.000 description 1
- RMINQIRDFIBNLE-NNRWGFCXSA-N O-[N-acetyl-alpha-neuraminyl-(2->6)-N-acetyl-alpha-D-galactosaminyl]-L-serine Chemical compound O1[C@H](OC[C@H](N)C(O)=O)[C@H](NC(=O)C)[C@@H](O)[C@@H](O)[C@H]1CO[C@@]1(C(O)=O)O[C@@H]([C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C1 RMINQIRDFIBNLE-NNRWGFCXSA-N 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 206010061534 Oesophageal squamous cell carcinoma Diseases 0.000 description 1
- 208000010191 Osteitis Deformans Diseases 0.000 description 1
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 description 1
- 206010061328 Ovarian epithelial cancer Diseases 0.000 description 1
- 206010073261 Ovarian theca cell tumour Diseases 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 208000027868 Paget disease Diseases 0.000 description 1
- 206010033372 Pain and discomfort Diseases 0.000 description 1
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 1
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 1
- 206010071776 Phyllodes tumour Diseases 0.000 description 1
- 208000009077 Pigmented Nevus Diseases 0.000 description 1
- 208000019262 Pilomatrix carcinoma Diseases 0.000 description 1
- 208000007641 Pinealoma Diseases 0.000 description 1
- 101710130420 Probable capsid assembly scaffolding protein Proteins 0.000 description 1
- 102000004079 Prolyl Hydroxylases Human genes 0.000 description 1
- 108010043005 Prolyl Hydroxylases Proteins 0.000 description 1
- 108010001267 Protein Subunits Proteins 0.000 description 1
- 102000002067 Protein Subunits Human genes 0.000 description 1
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- 108091006627 SLC12A9 Proteins 0.000 description 1
- 108010031271 Saccharomyces cerevisiae Proteins Proteins 0.000 description 1
- 101710204410 Scaffold protein Proteins 0.000 description 1
- 241000235347 Schizosaccharomyces pombe Species 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 208000000097 Sertoli-Leydig cell tumor Diseases 0.000 description 1
- 208000003252 Signet Ring Cell Carcinoma Diseases 0.000 description 1
- 208000009574 Skin Appendage Carcinoma Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 206010042553 Superficial spreading melanoma stage unspecified Diseases 0.000 description 1
- 108700025695 Suppressor Genes Proteins 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 description 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
- 206010043276 Teratoma Diseases 0.000 description 1
- 201000009365 Thymic carcinoma Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 102100031873 Transcriptional coactivator YAP1 Human genes 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 108010046308 Type II DNA Topoisomerases Proteins 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- 102100034079 Uncharacterized protein SPEM3 Human genes 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 208000006336 acinar cell carcinoma Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 208000021841 acute erythroid leukemia Diseases 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 108091005764 adaptor proteins Proteins 0.000 description 1
- 208000002517 adenoid cystic carcinoma Diseases 0.000 description 1
- 201000000452 adenoid squamous cell carcinoma Diseases 0.000 description 1
- 201000008395 adenosquamous carcinoma Diseases 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 208000020990 adrenal cortex carcinoma Diseases 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 208000007128 adrenocortical carcinoma Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 206010065867 alveolar rhabdomyosarcoma Diseases 0.000 description 1
- 208000006431 amelanotic melanoma Diseases 0.000 description 1
- 208000010029 ameloblastoma Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 230000014102 antigen processing and presentation of exogenous peptide antigen via MHC class I Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 238000011398 antitumor immunotherapy Methods 0.000 description 1
- 238000002617 apheresis Methods 0.000 description 1
- 201000007436 apocrine adenocarcinoma Diseases 0.000 description 1
- 201000005476 astroblastoma Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 201000007551 basophilic adenocarcinoma Diseases 0.000 description 1
- 208000001119 benign fibrous histiocytoma Diseases 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 208000007047 blue nevus Diseases 0.000 description 1
- 201000011143 bone giant cell tumor Diseases 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 201000003714 breast lobular carcinoma Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 101150073031 cdk2 gene Proteins 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000033026 cell fate determination Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000017455 cell-cell adhesion Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 201000002891 ceruminous adenocarcinoma Diseases 0.000 description 1
- 208000024188 ceruminous carcinoma Diseases 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 201000005217 chondroblastoma Diseases 0.000 description 1
- 201000010240 chromophobe renal cell carcinoma Diseases 0.000 description 1
- 208000021668 chronic eosinophilic leukemia Diseases 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 208000029664 classic familial adenomatous polyposis Diseases 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 201000010897 colon adenocarcinoma Diseases 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 208000011588 combined hepatocellular carcinoma and cholangiocarcinoma Diseases 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 102000007305 cyclin-dependent protein kinase activating kinase activity proteins Human genes 0.000 description 1
- 208000002445 cystadenocarcinoma Diseases 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000003436 cytoskeletal effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 229940029030 dendritic cell vaccine Drugs 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 201000009409 embryonal rhabdomyosarcoma Diseases 0.000 description 1
- 201000003908 endometrial adenocarcinoma Diseases 0.000 description 1
- 208000029382 endometrium adenocarcinoma Diseases 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 201000010877 epithelioid cell melanoma Diseases 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 201000005619 esophageal carcinoma Diseases 0.000 description 1
- 208000007276 esophageal squamous cell carcinoma Diseases 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 201000001169 fibrillary astrocytoma Diseases 0.000 description 1
- 201000008825 fibrosarcoma of bone Diseases 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000001448 gametogenic effect Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 208000015419 gastrin-producing neuroendocrine tumor Diseases 0.000 description 1
- 201000000052 gastrinoma Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 238000012226 gene silencing method Methods 0.000 description 1
- 230000004077 genetic alteration Effects 0.000 description 1
- 231100000118 genetic alteration Toxicity 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 201000002264 glomangiosarcoma Diseases 0.000 description 1
- 201000007574 granular cell carcinoma Diseases 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 210000002503 granulosa cell Anatomy 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 201000009277 hairy cell leukemia Diseases 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 208000006359 hepatoblastoma Diseases 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 208000029824 high grade glioma Diseases 0.000 description 1
- 230000017945 hippo signaling cascade Effects 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 231100000253 induce tumour Toxicity 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 206010073096 invasive lobular breast carcinoma Diseases 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000022013 kidney Wilms tumor Diseases 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000002332 leydig cell Anatomy 0.000 description 1
- 108020001756 ligand binding domains Proteins 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 125000003473 lipid group Chemical group 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 201000000014 lung giant cell carcinoma Diseases 0.000 description 1
- 208000012804 lymphangiosarcoma Diseases 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 201000010953 lymphoepithelioma-like carcinoma Diseases 0.000 description 1
- 208000003747 lymphoid leukemia Diseases 0.000 description 1
- 208000025036 lymphosarcoma Diseases 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 208000018013 malignant glomus tumor Diseases 0.000 description 1
- 201000006812 malignant histiocytosis Diseases 0.000 description 1
- 206010061526 malignant mesenchymoma Diseases 0.000 description 1
- 201000009020 malignant peripheral nerve sheath tumor Diseases 0.000 description 1
- 201000002338 malignant struma ovarii Diseases 0.000 description 1
- 208000027202 mammary Paget disease Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 208000000516 mast-cell leukemia Diseases 0.000 description 1
- 201000008749 mast-cell sarcoma Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 206010027191 meningioma Diseases 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 230000017205 mitotic cell cycle checkpoint Effects 0.000 description 1
- 230000037230 mobility Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 201000006894 monocytic leukemia Diseases 0.000 description 1
- 201000010879 mucinous adenocarcinoma Diseases 0.000 description 1
- 208000010492 mucinous cystadenocarcinoma Diseases 0.000 description 1
- 229940051875 mucins Drugs 0.000 description 1
- 201000005962 mycosis fungoides Diseases 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- 201000005987 myeloid sarcoma Diseases 0.000 description 1
- 208000001611 myxosarcoma Diseases 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 239000002070 nanowire Substances 0.000 description 1
- 208000014761 nasopharyngeal type undifferentiated carcinoma Diseases 0.000 description 1
- 210000001989 nasopharynx Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 208000007538 neurilemmoma Diseases 0.000 description 1
- 208000027831 neuroepithelial neoplasm Diseases 0.000 description 1
- 208000029974 neurofibrosarcoma Diseases 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- 230000006780 non-homologous end joining Effects 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 230000000683 nonmetastatic effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 208000012221 ovarian Sertoli-Leydig cell tumor Diseases 0.000 description 1
- 208000013371 ovarian adenocarcinoma Diseases 0.000 description 1
- 201000006588 ovary adenocarcinoma Diseases 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 208000004019 papillary adenocarcinoma Diseases 0.000 description 1
- 201000010198 papillary carcinoma Diseases 0.000 description 1
- 201000010210 papillary cystadenocarcinoma Diseases 0.000 description 1
- 208000024641 papillary serous cystadenocarcinoma Diseases 0.000 description 1
- 201000001494 papillary transitional carcinoma Diseases 0.000 description 1
- 208000031101 papillary transitional cell carcinoma Diseases 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940023041 peptide vaccine Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 208000028591 pheochromocytoma Diseases 0.000 description 1
- 230000000865 phosphorylative effect Effects 0.000 description 1
- 208000024724 pineal body neoplasm Diseases 0.000 description 1
- 201000004123 pineal gland cancer Diseases 0.000 description 1
- 208000021857 pituitary gland basophilic carcinoma Diseases 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 208000031223 plasma cell leukemia Diseases 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229940055019 propionibacterium acne Drugs 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 201000005825 prostate adenocarcinoma Diseases 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 201000008520 protoplasmic astrocytoma Diseases 0.000 description 1
- 208000013368 pseudoglandular squamous cell carcinoma Diseases 0.000 description 1
- 230000010490 psychological well-being Effects 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 102000016914 ras Proteins Human genes 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003307 reticuloendothelial effect Effects 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 102200127349 rs11547328 Human genes 0.000 description 1
- 201000007416 salivary gland adenoid cystic carcinoma Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 208000014212 sarcomatoid carcinoma Diseases 0.000 description 1
- 206010039667 schwannoma Diseases 0.000 description 1
- 201000008407 sebaceous adenocarcinoma Diseases 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 210000000717 sertoli cell Anatomy 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 201000008123 signet ring cell adenocarcinoma Diseases 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 201000002078 skin pilomatrix carcinoma Diseases 0.000 description 1
- 208000000649 small cell carcinoma Diseases 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 201000010700 sporadic breast cancer Diseases 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000011301 standard therapy Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 208000028210 stromal sarcoma Diseases 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 208000030457 superficial spreading melanoma Diseases 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 206010042863 synovial sarcoma Diseases 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 208000001644 thecoma Diseases 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 208000030901 thyroid gland follicular carcinoma Diseases 0.000 description 1
- 208000015191 thyroid gland papillary and follicular carcinoma Diseases 0.000 description 1
- 210000002105 tongue Anatomy 0.000 description 1
- 208000029335 trabecular adenocarcinoma Diseases 0.000 description 1
- 108091006105 transcriptional corepressors Proteins 0.000 description 1
- 108091006107 transcriptional repressors Proteins 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 208000023747 urothelial carcinoma Diseases 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 229940023147 viral vector vaccine Drugs 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4634—Antigenic peptides; polypeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464499—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4648—Bacterial antigens
- A61K39/464817—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
Definitions
- the present invention relates to the field of cancer therapy.
- the present invention relates to a method of preventing, treating or inhibiting the development of tumours and/or metastases in a subject.
- tumour promotion In humans with advanced cancer, anti-tumour immunity becomes ineffective due to the tightly regulated interplay of pro- and anti-inflammatory, immune- stimulatory and immunosuppressive signals. For example, loss of the antiinflammatory signals leads to chronic inflammation and prolonged proliferative signalling. Interestingly, cytokines that both promote and suppress proliferation of the tumour cells are produced at the tumour site. It is the imbalance between the effects of these various processes that results in tumour promotion.
- tumour immunosurveillance a major barrier to attempts to develop effective immunotherapy for cancer has been an inability to break immunosuppression at the cancer site and restore normal networks of immune reactivity.
- the physiological approach of immunotherapy is to normalize the immune reactivity so that, for example, the endogenous tumour antigens would be recognized and effective cytolytic responses would be developed against tumour cells.
- tumour immunosurveillance it was once unclear if tumour immunosurveillance existed, it is now believed that the immune system constantly monitors and eliminates newly transformed cells. Accordingly, cancer cells may alter their phenotype in response to immune pressure in order to escape attack (immunoediting) and upregulate expression of inhibitory signals. Through immunoediting and other subversive processes, primary tumour and metastasis maintain their own survival.
- Tumour associated antigens can be recognised by autologous antibodies and T cells and are capable of inducing tumour-directed immune responses.
- Many TAAs are now potential targets for immunotherapies, being prepared as part of a "cancer vaccine”.
- cancer treatment vaccines must achieve two goals. First, they must stimulate specific immune responses against the correct target and, second, the immune responses must be powerful enough to overcome the barriers that cancer cells use to protect themselves from attack by immune cells. In the context of therapy based on administration of TAAs, there is a problem in that TAAs are often at the core self-antigens, so the immune system is geared towards not responding to them. Therefore, there can be a lack of effective targeting to dendritic cells and consequently a lack of induction of effective anti- tumour Type 1 responses.
- the present invention provides an effective method for treating and/or preventing cancer and/or the establishment of metastases by administering selective tumour associated antigens together with a whole cell Mycobacterium.
- a non-viable whole cell Mycobacterium and a tumour associated antigen as a combined preparation for simultaneous, separate, or sequential use in the treatment of a neoplastic disease.
- a method of treating, reducing, inhibiting or controlling a neoplastic disorder in a subject comprises simultaneously, separately or sequentially administering a method for treating a neoplastic disorder in a patient, comprising administering to the patient a non-viable whole cell Mycobacterium and one or more tumour associated antigens, wherein the disorder is characterised by the presence of said one or more antigens, and wherein the antigen(s) to be administered to the patient have genetic homology to exogenous sequences in said Mycobacterium.
- a non-viable Mycobacterium for therapeutic use in priming dendritic cells in a patient suffering a neoplastic disorder, wherein the Mycobacterium is M.
- obuense IMM-101
- the disorder is characterised by the presence of one or more of the following tumour associate antigens: ERBB2, CDK4, RASK, WTIP, CDC27, MAGEA1 , MUC5AC, TP53, or CSAG2.
- the Mycobacterium is M.
- vaccae (NCTC1 1695) and the disorder is characterised by the presence of one or more of the following tumour associated antigens: CDK4, ERBB2, RASK, PTPRC, GAGE7, MUC5A, GAGE2b, TP53, GAGE2a, CDC27, MSLN, MAGEA1 , MUC16, REC04, or SSX2.
- the present invention therefore provides a combination therapy of specific tumour associated antigens together with a specific Mycobacterium.
- the inventors have found that the combination of both therapies has benefits over the administration of TAAs only. Description of the Drawings
- IMM-101 M. obuense
- Figure 2 illustrates (A) Flow cytometric analysis of the activation/maturation or (B) ELISA of cell culture supernatants from murine GMCSF bone marrow derived DCs following overnight stimulation with 10, 100 or 300pg/ml IMM-101 ,
- C Flow cytometric analysis or of the activation/maturation or
- D CBA analysis of culture supernatants from human monocyte derived DCs following overnight culture with 10, 100 or 300 g/ml IMM-101 , PBS, or 250ng/ml LPS (one example donor from 2 repeats).
- IMM-101 Flow cytometric analysis or of the activation/maturation or
- D CBA analysis of culture supernatants from human monocyte derived DCs following overnight culture with 10, 100 or 300 g/ml IMM-101 , PBS, or 250ng/ml LPS (one example donor from 2 repeats).
- * p ⁇ 0.05, ** p ⁇ 0.01 , *** p ⁇ 0.001 This shows the ability of M. obuense (IMM101 ) to prime dendritic cells.
- FIG. 3 illustrates CFSE-labeled OVA specific OTII CD4 + T cells were cultured for 72 hours alone (T cells'), with murine GMCSF bone marrow derived DCs that had been pre-exposed to IMM-101 ( ⁇ '), or with control, non-exposed DCs ('Media'), with the addition of OVA peptide (0.01 pg/ml) or OVA protein (5 pg/ml).
- A Flow cytometric histograms showing cell proliferation CFSE dilution in OTII T cells and
- B the percentage of T cells in each proliferation peak ( ⁇ SEM). This shows the ability of M. obuense (IMM101) to effectively prime dendritic cells and the positive effect on presentation to CD4 + cells.
- Figure 4 illustrates (A) Mice were injected s.c. with IMM-101 -activated or control (media) GMCSF bone marrow derived DCs or Propionibacterium acnes (P.acnes)-activated GMGSF bone marrow-derived DCs. 7 days later, draining lymph nodes were removed, and lymph node (LN) cells cultured for 72 hours with media, 100pg/ml IMM-101 , 10pg/ml P. acnes or 16.67pg/ml plate bound anti-CD3.
- B Cytokine levels in culture supernatants were determined by ELISA ( ⁇ SEM). (* p ⁇ 0.05, ** p ⁇ 0.01 , *** p ⁇ 0.001).
- the present invention provides an effective means to treat neoplastic disorders with immunotherapy.
- the realisation that mycobacteria share sequence homology with certain TAAs allows the mycobacteria to be utilised in therapies designed to treat neoplastic disorders using TAAs.
- the mycobacteria are shown to activate dendritic cells for effective antigen presentation and help provide a powerful immune response to overcome the barriers that cancer cells use to protect against attack by immune cells such as cytotoxic T cells, natural killer cells and macrophages.
- immune cells such as cytotoxic T cells, natural killer cells and macrophages.
- tumour refers to a cell or population of cells whose growth, proliferation or survival is greater than growth, proliferation or survival of a normal counterpart cell, e.g. a cell proliferative or differentiative disorder. Typically, the growth is uncontrolled.
- malignancy refers to invasion of nearby tissue.
- metastasis refers to spread or dissemination of a tumour, cancer or neoplasia to other sites, locations or regions within the subject, in which the sites, locations or regions are distinct from the primary tumour or cancer.
- terapéuticaally effective amount is defined as an amount of a TAA, in combination with a Mycobacterium, that preferably results in a decrease in severity of disease symptoms, an increase in frequency and duration of disease symptom-free periods, or a prevention of impairment or disability due to the disease affliction.
- effective amount or “pharmaceutically effective amount” refer to a sufficient amount of an agent to provide the desired biological or therapeutic result. That result can be reduction, amelioration, palliation, lessening, delaying, and/or alleviation of one or more of the signs, symptoms, or causes of a disease, or any other desired alteration of a biological system.
- an effective amount may comprise an amount sufficient to cause a tumour to shrink and/or to decrease the growth rate of the tumour (such as to suppress tumour growth) or to prevent or delay other unwanted cell proliferation.
- an effective amount is an amount sufficient to delay development, or induce stabilisation of the cancer or tumour. It may also prolong survival.
- a therapeutically effective amount is an amount sufficient to prevent or delay recurrence.
- a therapeutically effective amount can be administered in one or more administrations.
- the therapeutically effective amount of the therapeutic preparation or preparations may result in one or more of the following: (i) reduce the number of cancer cells; (ii) reduce tumour size; (iii) inhibit, retard, slow to some extent and preferably stop cancer cell infiltration into peripheral organs; (iv) inhibit (i.e., slow to some extent and preferably stop) tumour metastasis; (v) inhibit tumour growth; (vi) prevent or delay occurrence and/or recurrence of tumour; and/or (vii) relieve to some extent one or more of the symptoms associated with the cancer.
- a "therapeutically effective dosage” may induce tumour shrinkage by at least about 5 % relative to baseline measurement, such as at least about 10 %, or about 20 %, or about 60 % or more.
- the baseline measurement may be derived from untreated subjects.
- a therapeutically effective amount of a therapeutic preparation or preparations can decrease tumour size, or otherwise ameliorate symptoms in a subject.
- One of ordinary skill in the art would be able to determine such amounts based on such factors as the subject's size, the severity of the subject's symptoms, and the particular composition or route of administration selected.
- immune response refers to the action of, for example, lymphocytes, antigen presenting cells, phagocytic cells, granulocytes, and soluble macromolecules produced by the above cells or the liver (including antibodies, cytokines, and complement) that results in selective damage to, destruction of, or elimination from the human body of cancerous cells.
- treatment refers to administering an active agent with the purpose to cure, heal, alleviate, relieve, alter, remedy, ameliorate, improve, or affect a condition (e.g., a disease), the symptoms of the condition, or to prevent or delay the onset of the symptoms, complications, biochemical indicia of a disease, or otherwise arrest or inhibit further development of the disease, condition, or disorder in a statistically significant manner.
- a condition e.g., a disease
- the term "subject” is intended to include human and non- human animals. Preferred subjects include human patients in need of enhancement of an immune response.
- the methods are particularly suitable for treating human patients having a neoplastic disorder. In a particular embodiment, the methods are particularly suitable for treatment of cancer cells in vivo.
- the terms "concurrent administration” or “concurrently” or “simultaneous”, “sequential” or “separate” mean that administration of the Mycobacterium and TAA occur as part of the same treatment regimen.
- “Simultaneous” administration includes the administration of the Mycobacterium and one or more TAAs within about 2 hours or about 1 hour or less of each other, even more preferably at the same time.
- “Separate” administration includes the administration of the Mycobacterium and one or more TAAs, more than about 12 hours, or about 8 hours, or about 6 hours or about 4 hours or about 2 hours apart.
- “Sequential” administration includes the administration of the Mycobacterium and one or more TAAs each in multiple aliquots and/or doses and/or on separate occasions.
- the Mycobacterium may be administered to the patient after before and/or after administration of the one or more TAAs. Alternatively, the Mycobacterium is continued to be applied to the patient after treatment with the one or more TAAs.
- “about” means within an acceptable error range for the particular value as determined by one of ordinary skill in the art, which will depend in part on how the value is measured or determined, i.e., the limitations of the measurement system. For example, “about” can mean within 1 or more than 1 standard deviation per the practice in the art. Alternatively, “about” can mean a range of up to 20%. When particular values are provided in the application and claims, unless otherwise stated, the meaning of "about” should be assumed to be within an acceptable error range for that particular value.
- the Mycobacterium is non-viable, e.g. is a heat-killed Mycobacterium, preferably a whole cell Mycobacterium.
- mycobacterial species for use in the present invention include M. vaccae, M. thermoresistibile, M. flavescens, M. duvalii, M. phlei, M. obuense, M. parafortuitum, M. sphagni, M. aichiense, M. rhodesiae, M. neoaurum, M. chubuense, M. tokaiense, M. komossense, M. aurum, M. w, M. tuberculosis, M. microti; M.
- the heat-killed Mycobacterium is non-pathogenic.
- the nonpathogenic heat-killed Mycobacterium is preferably selected from M. vaccae, M. obuense, M. parafortuitum, M. aurum, M. indicus pranii, M. phlei and combinations thereof. More preferably the non-pathogenic heat-killed Mycobacterium is a rough variant.
- the amount of Mycobacterium administered to the patient is sufficient to elicit a protective immune response in the patient such that the patient's immune system is able to mount an effective immune response to the cancer or tumour.
- a containment means comprising the effective amount of heat-killed Mycobacterium or use in the present invention, which typically may be from 10 3 to 10 11 organisms, preferably from 10 4 to 10 10 organisms, more preferably from 10 6 to 10 10 organisms, and even more preferably from 10 6 to 10 9 organisms.
- the effective amount of heat-killed Mycobacterium for use in the present invention may be from 10 3 to 10 11 organisms, preferably from 10 4 to 10 10 organisms, more preferably from 10 6 to 10 10 organisms, and even more preferably from 10 6 to 10 9 organisms.
- the amount of heat-killed Mycobacterium for use in the present invention is from 10 7 to 10 9 cells or organisms.
- the composition according to the present invention may be administered at a dose of from 10 8 to 10 9 cells for human and animal use. Alternatively the dose is from 0.01 mg to 1 mg or from 0.1 mg to 1 mg organisms presented as either a suspension or dry preparation.
- M. vaccae and M. obuense are particularly preferred.
- M. obuense is sometimes referred to as IMM-101 and a suitable exemplary strain is deposited under the NCTC accession number, NCTC13365.
- a suitable exemplary strain of M.vaccae is deposited under the NCTC accession number NCTC1 1659.
- the present invention may be used to treat a neoplastic disease, such as solid or non-solid cancers.
- treatment encompasses the prevention, reduction, control and/or inhibition of a neoplastic disease.
- diseases include a sarcoma, carcinoma, adenocarcinoma, melanoma, myeloma, blastoma, glioma, lymphoma or leukemia.
- Exemplary cancers include, for example, carcinoma, sarcoma, adenocarcinoma, melanoma, neural (blastoma, glioma), mesothelioma and reticuloendothelial, lymphatic or haematopoietic neoplastic disorders (e.g., myeloma, lymphoma or leukemia).
- a neoplasm, tumour or cancer includes a lung adenocarcinoma, lung carcinoma, diffuse or interstitial gastric carcinoma, colon adenocarcinoma, prostate adenocarcinoma, esophagus carcinoma, breast carcinoma, pancreas adenocarcinoma, ovarian adenocarcinoma, adenocarcinoma of the adrenal gland, adenocarcinoma of the endometrium or uterine adenocarcinoma.
- Neoplasia, tumours and cancers include benign, malignant, metastatic and non- metastatic types, and include any stage (I, II, III, IV or V) or grade (G1 , G2, G3, etc.) of neoplasia, tumour, or cancer, or a neoplasia, tumour, cancer or metastasis that is progressing, worsening, stabilized or in remission.
- Cancers that may be treated according to the invention include but are not limited to cells or neoplasms of the bladder, blood, bone, bone marrow, brain, breast, colon, esophagus, gastrointestines, gum, head, kidney, liver, lung, nasopharynx, neck, ovary, prostate, skin, stomach, testis, tongue, or uterus.
- the cancer may specifically be of the following histological type, though it is not limited to the following: neoplasm, malignant; carcinoma; carcinoma, undifferentiated; giant and spindle cell carcinoma; small cell carcinoma; papillary carcinoma; squamous cell carcinoma; lymphoepithelial carcinoma; basal cell carcinoma; pilomatrix carcinoma; transitional cell carcinoma; papillary transitional cell carcinoma; adenocarcinoma; gastrinoma, malignant; cholangiocarcinoma; hepatocellular carcinoma; combined hepatocellular carcinoma and cholangiocarcinoma; trabecular adenocarcinoma; adenoid cystic carcinoma; adenocarcinoma in adenomatous polyp; adenocarcinoma, familial polyposis coli; solid carcinoma; carcinoid tumour, malignant; bronchiolo-alveolar adenocarcinoma; papillary adenocarcinoma; chromophobe carcinoma
- the neoplastic disease may be tumours associated with a cancer selected from prostate cancer, liver cancer, renal cancer, lung cancer, breast cancer, colorectal cancer, pancreatic cancer, brain cancer, hepatocellular cancer, lymphoma, leukaemia, gastric cancer, cervical cancer, ovarian cancer, thyroid cancer, melanoma, head and neck cancer, skin cancer and soft tissue sarcoma and/or other forms of carcinoma.
- the tumour may be metastatic or a malignant tumour.
- the neoplastic disease to be treated is pancreatic cancer, breast cancer, lung cancer, ovarian cancer, colorectal cancer, prostate cancer and skin cancer.
- the neoplastic disease to be treated is pancreatic cancer.
- the neoplastic disease to be treated is lung cancer.
- the neoplastic disease to be treated is colorectal cancer.
- the therapy is used to reduce or inhibit metastasis of a primary tumour or cancer to other sites, or the formation or establishment of metastatic tumours or cancers at other sites distal from the primary tumour or cancer, thereby inhibiting or reducing tumour or cancer relapse or tumour or cancer progression.
- methods of the invention include, one or more of the following: 1) reducing or inhibiting growth, proliferation, mobility or invasiveness of tumour or cancer cells that potentially or do develop metastases, 2) reducing or inhibiting formation or establishment of metastases arising from a primary tumour or cancer to one or more other sites, locations or regions distinct from the primary tumour or cancer; 3) reducing or inhibiting growth or proliferation of a metastasis at one or more other sites, locations or regions distinct from the primary tumour or cancer after a metastasis has formed or has been established, 4) reducing or inhibiting formation or establishment of additional metastasis after the metastasis has been formed or established, 5) prolonged overall survival, 6) prolonged progression free survival, or 7) disease stabilisation.
- the therapeutic effect may not take effect immediately.
- treatment may be followed by an increase in the neoplasia, tumour or cancer cell numbers or mass, but over time eventual stabilization or reduction in tumour cell mass, size or numbers of cells in a given subject may subsequently occur.
- Additional adverse symptoms and complications associated with neoplasia, tumour, cancer and metastasis that can be inhibited, reduced, decreased, delayed or prevented include, for example, nausea, lack of appetite, lethargy, pain and discomfort.
- a partial or complete decrease or reduction in the severity, duration or frequency of an adverse symptom or complication associated with or caused by a cellular hyperproliferative disorder, an improvement in the subjects quality of life and/or well-being, such as increased energy, appetite, psychological well-being, are all particular non-limiting examples of therapeutic benefit.
- a therapeutic benefit or improvement therefore can also include a subjective improvement in the quality of life of a treated subject.
- a method prolongs or extends lifespan (survival) of the subject.
- a method improves the quality of life of the subject.
- the Mycobacterium for use according to the invention is administered in combination with one or more TAAs that share genetic sequence homology with the Mycobacterium.
- the term "genetic sequence homology" is intended to mean that the sequence of a TAA is significantly similar to a genetic sequence in the Mycobacterium.
- the sequence similarity can be derived by carrying out a BLAST (Basic Local Alignment Search Tool) alignment and analysis between a TAA and the mycobacterial generic sequence.
- the BLAST method using the BLAST software version 2.2.28 (available at www.blast.ncbi.nlm.nih.gov/Blast.cqi), using the heuristic based algorithm identifies similar sequences by locating short matches between two sequences - known as seeding, allowing identification and scoring for the significance of each alignment according to the BLAST algorithm.
- the BLAST algorithm locates all common sequences of interest (cased on amino acid alignment) and aligns them to a preferred database or reference sequence, e.g. the genome sequences of the Mycobacterium. The sequences identified are then used to assemble aligned sequences and identify homologous regions and scored for significance according to key criteria including e-value scores.
- the parameters used to identify homologues were "stringent” parameters. This required the “alignment length” to be at least 50 base pairs (bp) and an “e-val” score to be less than 0.5.
- the therapy comprises administration of M. obuense in combination with one or more of the TAAs identified in Table 1.
- Table 1 TAA with homologies to sequences in M. obuense NCTC13365.
- target TAAs with a restricted expression pattern in normal tissues need to be identified.
- target TAAs should be expressed in high frequency in tumour tissue and induce strong adaptive immune responses to confirm their immunogenic potential.
- TAA showing homologies with M. obuense NCTC13365 may offer potential as suitable immunotherapeutic targets.
- Cyclin-dependent Kinase 4 is a member of the Ser/Thr kinase family.
- the human protein shares 94% and 95% aa sequence identity with the mouse and rat orthologs, respectively.
- CDK4 shuttles between the cytoplasm and nucleus as part of its role in cell cycle regulation. It promotes the transition from G1 to S phase by phosphorylating and inactivating RB1. Activation of CDK4 requires binding of a D-type Cyclin and phosphorylation of Thr172 by the CAK
- CDK4s might play a significant role in malignant disease.
- Amplification of the CDK4 gene, located at 12q13-q14, has been found as an alternative genetic alteration to CDKN2A inactivation in various human tumors including malignant gliomas and sarcomas (An et al, 1999).
- a somatic point mutation (R24C) of the CDK4 gene was identified in human melanomas, causing a tumor-specific antigen and disrupting the interaction between CDK4 and its inhibitor p16 and is recognized by CD8+ cells (Wolfel et al., 1995).
- CDK4 has been suggested to be a prognostic marker for hepatocellular carcinoma and its kinase activity has been reported to promote the progression of T cell acute lymphoblastic leukemia; however, CDK4 failed to discriminate between healthy and malignant pancreatic tissue (Altirriba et al., 2012).
- ErbB2 or Her2/neu is a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. This protein has no ligand binding domain of its own and therefore cannot bind growth factors. However, it does bind tightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways, such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase.
- EGF epidermal growth factor
- ErbB2/Her2 is considered an oncogene; it is selectively over-expressed in a broad variety of human tumors including 25-40% of breast, ovarian, gastric, renal, esophageal and colorectal carcinomas and a small proportion of human melanomas (Selinger et al., 2000; Mimura et al., 2005; Al-kuraya et al., 2007). As a cell surface molecule it is accessible both to antibody- and T cell-based approaches. Moreover, ErbB2/Her2 can be regarded as an indispensable tumor antigen, since tumors over-expressing this protein are dependent on this oncogene for their survival and silencing consequently leads to growth arrest and/or apoptosis induction.
- Nepoletano and colleagues described the generation of an allogenic microvesicle cell factory in which the expression of a specific tumor antigen was combined to the expression of co-stimulatory and allogeneic molecules.
- the DG75 lymphoblastoid cell line was selected as microvesicle producer and transfected with ErbB2/Her2, as tumor antigen prototype.
- the shed microvesicles transferred antigenic components to recipient DCs, increasing their immunogenicity.
- DC pulsing resulted in cross-presentation of ErbB2/Her2 both in MHC class I and MHC class II compartments, and ErbB2/Her2-specific CD8+ T cells from cancer patients were activated by DCs pulsed with vesicle- bound ErbB2.
- Mutant p21-ras proteins contain sequences that distinguish them from normal ras, and represent unique epitopes for T-cell recognition of antigen-bearing tumour cells.
- Gjertsen and colleagues (1997) examined the capacity of CD4+ and CD8+ T cells, generated simultaneously by mutant-ras-peptide vaccination of a pancreatic-adenocarcinoma patient, to recognize and lyse autologous tumour cells harbouring corresponding activated K-ras epitopes.
- the patient was vaccinated with a purified 17mer ras peptide (KLVWG AVG VG KS ALT I ) , containing the Gly12 -> Val substitution.
- T cells were cloned following peptide stimulation, and CD4+ and CD8+ peptide-specific cytotoxic T lymphocytes were obtained.
- Transient pancreatic-adenocarcinoma cell lines were established in cell culture from malignant ascites of the patient, and were shown to harbour the same K-ras mutation as found in the primary tumour. These cells were efficiently killed by the T-cell clones and CD8+-mediated cytotoxicity was MHC-class-l-restricted, as demonstrated by inhibition of lysis by anti-class-l monoclonal antibodies.
- WTIP Wild Tumor 1 Interacting Protein
- WTIP is a protein coding gene. Diseases associated with WTIP include Wlms tumour. WTIP is an adapter or scaffold protein which participates in the assembly of numerous protein complexes and is involved in several cellular processes such as cell fate determination, cytoskeletal organization, repression of gene transcription, cell-cell adhesion, cell differentiation, proliferation and migration. It also positively regulates microRNA (miRNA)-mediated gene silencing and negatively regulates Hippo signaling pathway and antagonizes phosphorylation of YAP1.
- miRNA microRNA
- WTIP may be a promising immunotherapeutic target.
- vaccine-induced immunological responses could be detected in patients with either haematological or solid cancers.
- objective responses, such as stable disease were recorded in these patients (reviewed in van Driessche et al., 2012)
- the protein encoded by this gene shares strong similarity with Saccharomyces cerevisiae protein Cdc27, and the gene product of Schizosaccharomyces pombe nuc 2.
- This protein is a component of the anaphase-promoting complex (APC), which is composed of eight protein subunits and is highly conserved in eukaryotic cells.
- APC anaphase-promoting complex
- This complex catalyzes the formation of cyclin B-ubiquitin conjugate, which is responsible for the ubiquitin-mediated proteolysis of B-type cyclins.
- the protein encoded by this gene and three other members of the APC complex contain tetratricopeptide (TPR) repeats, which are important for protein- protein interactions.
- TPR tetratricopeptide
- This protein was shown to interact with mitotic checkpoint proteins including Mad2, p55CDC and BUBR1 , and it may thus be involved in controlling the timing of mitosis.
- a mutation in CDC27 causing altered protein trafficking into the endosomal compartment was found in a melanoma. This allows for the presentation of an MHC class II epitope and recognition by CD4 + cells (Wang et al., 1999).
- MAGE Melanoma Antigen Gene
- CTA cancer-testis antigens
- MAGE-A may effect transcriptional repressor proteins, promoting tumour survival by supressing p53, which is involved in apoptosis and senescence (Meek and Marcar, 2012; Weon and Potts, 2015).
- MAGE-A are also broadly immunogenic and for this reason offer potential in cancer immunotherapy (Daudi et al., 2014).
- MAGE proteins have received increased attention in recent years as immunotherapeutic targets. Whereas a large Phase III trial in lung cancer (MAGRIT) has failed to show a therapeutic effect of targeting MAGE-A3 as measured by increase in disease-free survival vs placebo, the potential remains with alternative drug combinations and approaches (Ruiz et al., 2014).
- MUC5AC is a member of the mucin family, and as such expressed in mucotic tissue including the lung, the gastrointestinal tract and the pancreas.
- the mucin family consists of a heterogeneous group of 21 high molecular weight O- glycoproteins that can be either secreted or are membrane bound.
- Mucins, in particular MUC1 have been used in TAA cancer vaccines, more than 60 clinical trials are in progress and three have reached phase IIB/III; BLP25 a lyposomal vaccine, TG4010 which uses a recombinant modified vaccinia Ankara virus and an oxidized mannan MUC1 (reviewed in Roulois et al., 2013).
- MUC5AC could also become a relevant immunotherapeutic target.
- MUC5A is not expressed in healthy tissue but is detected in precursor neoplastic lesions and in tumour tissue (Kim et al., 2002).
- MUC5AC accelerates progression of pancreatic cancer adenocarcinoma and at least in vitro its inhibition reduces invasiveness (Yamazoe et al. 2010).
- treatment with mAbs targeting MUC5AC showed therapeutic activity, with patients remaining stable and reaching greater than 12 months survival after having progressed on standard therapy (Morse et al., 2012; Patel et al., 2014). Based on these initial results, a phase II study of NEO-102 given in combination with gemcitabine is on-going in patients with refractory pancreatic cancer.
- the TP53 is a tumour suppressor gene.
- the p53 protein binds DNA and induces production of p21 which when complexed to cdk2 prevents cells from undergoing cell division. Mutations in p53 interfere with the DNA binding step so that p21 is no longer produced and cells are allowed to divide uncontrollably. Approximately 50% of all tumours exhibit mutations and overexpression of p53, making this protein an interesting candidate target for immunotherapy of cancer. Early preclinical studies have shown that adoptive transfer of p53-specific cytotoxic T cells was able to eradicate tumours overexpressing p53 (Vierboom et al., 1997).
- Chondrosarcoma-associated gene 2/3 protein also known as Taxol-resistant associated gene-3, belongs to the cancer testis antigen family. It appears to be associated with neoplastic phenotype and with resistance to chemotherapeutic agents. There is not as much known about this TAA compared to others listed in Table 1 , but studies investigating gene expression profiling in cancer patients and expression in cancer cell lines and biopsy specimens has identified CSAG2 in a variety of cancers including melanoma, ovarian, bladder and prostate cancer as worthy of consideration as potential immunotherapy target antigen (Karam et al., 201 1 ; Beard et al., 2013; Takahashi et al., 2015).
- the therapy comprises the administration of M. vaccae in combination with one or more of the TAAs identified in Table 2.
- the term "combination" as used throughout the specification, is meant to encompass the administration of the Mycobacterium simultaneously, separately or sequentially with administration of the TAA. Accordingly, the TAA and the Mycobacterium may be present in the same or separate pharmaceutical formulations, and administered at the same time or at different times.
- a Mycobacterium and the TAA may be provided as separate medicaments for administration at the same time or at different times.
- a Mycobacterium and TAA are provided as separate medicaments for administration at different times.
- either the Mycobacterium or TAA may be administered first; however, it is suitable to administer the Mycobacterium followed by the TAA.
- both can be administered on the same day or at different days, and they can be administered using the same schedule or at different schedules during the treatment cycle.
- a treatment cycle consists of the administration of a Mycobacterium daily, weekly, fortnightly or monthly, simultaneously with TAA weekly.
- the Mycobacterium is administered before and/or after the administration of the TAA.
- the administration of TAA may be performed simultaneously with the administration of the effective amounts of the Mycobacterium.
- the whole cell heat-killed Mycobacterium may be administered to the patient via the parenteral, intratumoral, oral, sublingual, nasal or pulmonary route.
- it is administered via a parenteral route selected from subcutaneous, intradermal, subdermal, intraperitoneal, intravenous and intravesicular injection. More preferably, administration comprises intratumoural injection of the mycobacterial preparation.
- the effective amount of the Mycobacterium may be administered as a single dose.
- the effective amount of the Mycobacterium may be administered in multiple (repeat) doses, for example two or more, three or more, four or more, five or more, ten or more, or twenty or more repeat doses.
- the Mycobacterium may be administered between about 4 weeks and about 1 day prior to TAA therapy, such as between about 4 weeks and 1 week, or about between 3 weeks and 1 week, or about between 3 weeks and 2 weeks. Administration may be presented in single or multiple doses.
- non-viable Mycobacterium for therapeutic use in priming dendritic cells in a patient suffering a neoplastic disorder
- the Mycobacterium is M.
- obuense I MM 1 -01
- the disorder is characterised by the presence of one or more of the following tumour associate antigens (TAAs): ERB2, CDK4, RASK, WTIP, CDC27, MAGEA1 , MUC5AC, TP53, or CSAG2.
- TAAs tumour associate antigens
- ERB2 tumour associate antigens
- CDK4 tumour associate antigens
- RASK tumour associate antigens
- WTIP CDC27
- MAGEA1 MUC5AC
- TP53 TP53
- CSAG2 tumour associate antigens
- vaccae and the disorder is characterised by the presence of one or more of the following tumour associated antigens: CDK4, ERBB2, RASK, PTPRC, GAGE7, MUC5A, GAGE2b, TP53, GAGE2a, CDC27, MSLN, MAGEA1 , MUC16, REC04, or SSX2.
- tumour associated antigens CDK4, ERBB2, RASK, PTPRC, GAGE7, MUC5A, GAGE2b, TP53, GAGE2a, CDC27, MSLN, MAGEA1 , MUC16, REC04, or SSX2.
- a method of treating a neoplastic disorder in a patient comprising administering to the patient a nonviable whole cell Mycobacterium and one or more tumour associated antigens (TAAs), wherein the disorder is characterised by the presence of said one or more antigens, and wherein the antigen(s) to be administered to the patient have genetic homology to exogenous sequences in said Mycobacterium.
- TAAs tumour associated antigens
- Mycobacterial compositions according to the invention will comprise an effective amount of mycobacteria typically dispersed in a pharmaceutically acceptable carrier.
- pharmaceutically or pharmacologically acceptable refers to molecular entities and compositions that do not produce an adverse, allergic or other untoward reaction when administered to an animal, such as, for example, a human, as appropriate.
- the preparation of an pharmaceutical composition that contains mycobacteria will be known to those of skill in the art in light of the present disclosure, as exemplified by Remington's Pharmaceutical Sciences, 18th Ed. Mack Printing Company, 1990, Moreover, for animal (e.g., human) administration, it will be understood that preparations should meet sterility, pyrogenicity, general safety and purity standards.
- a pharmacologically acceptable carrier as described herein is borate buffer or sterile saline solution (0.9% NaCI).
- pharmaceutically acceptable carrier includes any and all solvents, dispersion media, coatings, surfactants, antioxidants, preservatives e.g., antibacterial agents, antifungal agents), isotonic agents, absorption delaying agents, salts, preservatives, drugs, drug stabilizers, gels, binders, excipients, disintegration agents, lubricants, sweetening agents, flavouring agents, dyes, such like materials and combinations thereof, as would be known to one of ordinary skill in the art (see, for example, Remington's Pharmaceutical Sciences, 18th Ed. Mack Printing Company, 1990, pp. 1289-1329).
- Example 1 Example 1
- BLAST Basic Local Alignment Search Tool
- the BLAST algorithm locates all common sequences of interest (based on amino acid alignment) and aligns them to a preferred database or reference sequence - in this case the genome sequences of M. obuense NCTC13365.
- the sequences identified are then used to assemble aligned sequences and identify homologous regions and scored for significance according key criteria including e-value scores.
- key criteria were determined to improve the significance of the homologies identified. These included requiring an alignment length of at least 50bp and an "e-val" score as close as possible to 0, so only "e- val” score less than 0.5 were taken.
- a total of 218 sequences were blasted onto M. obuense NCTC13365.
- TAA genes were identified showing homologies with sequences in M. obuense NCTC13365. These are listed in Table 1. The raw data resulting from the search is shown in Table 3. Table 3. TAAs with sequence homology to sequences in M.obuense NCTC13365.
- IMM-101 effects of IMM-101 on dendritic cell activation were assessed in order to determine whether IMM-101 enhances therapeutic efficacy by priming the immune system against recognition of tumour associated antigens (TAAs).
- TAAs tumour associated antigens
- mouse bone marrow- derived dendritic cells were obtained from single cell suspensions of mouse femours and cultured in petri dishes with GM-CSF for 10 days, which included three regularly spaced media changes.
- Mouse BMDCs cells were then harvested and incubated overnight with 10 pg/ml, 100 pg/ml, or 300 pg/ml IMM- 101 , LPS, Pam3 or control (1 x phosphate buffered saline).
- Mouse peripheral blood mononuclear cells were then further harvested and phenotypic activation was assessed by FACS analysis ( Figure 2a - CD40, CD83 and CD86). Supernatants from mouse PBMCs were also removed and analysed for the cytokine secretion profile by FACS ( Figure 2b— IL12 and IL6).
- HMDCs human monocyte-derived DCs
- PBMCs peripheral blood mononuclear cells
- IL-4 and GM-CSF GM-CSF
- HMDCs were harvested and phenotypic activation in the presence of 10 pg/ml, 100 pg/ml, or 300 pg/ml IMM- 101 , LPS, or control (1 x phosphate buffered saline) were assessed by FACS (CD80 and CD86).
- Supernatants were removed and cytokine secretion levels were measured by ELISA ( Figure 2d - IL-6 and IL-12p40). The results demonstrate that incubating either mouse or human DCs with IMM-101 causes De activation.
- BMDCs were pre-pulsed with IMM-101 and added to cultures of CD4+ T cells isolated from the lymph nodes and spleens of transgenic OTII mice stimulated with ovalbumin (Ova) peptide or Ova protein.
- Ovalbumin is a mildly immunogenic glycoprotein that is often used as a key reference protein in vaccine-based experiments. The experiments were performed alongside a control with non-exposed DCs (Media), or T-cells cultured alone. The co- cultures were incubated for 72 hours. T cells in culture were stained with CFSE to assess proliferation via flow cytometry. ( Figure 3).
- the CD4+ T cells of OTII mice all express transgenic Ova-specific CD4 + -T cell receptors. CFSE staining allows for the number of divisions of the T cell populations to be quantified as the dye dilutes with each division.
- IMM-101 influences bacterial uptake and/or processing, as evidenced by the increased number of divisions of CFSE-stained T-cells upon incubation with OVA protein in the presence of IMM-101 -activated DCs, versus control ( Figure 3). This shows the ability of IMM-101 to effectively prime dendritic cells, with a positive effect on the presentation of antigens to CD4 + cells.
- IMM-101 -primed DCs can activate the immune system against TAAs
- mice were injected subcutaneously in the footpad with IMM-101 -primed or control (Media) GMCSF bone marrow-derived DCs. Media DCs were not primed with IMM-101. As a control, the experiment was performed alongside P.acnes-stimulated DCs. Seven days later, popliteal draining lymph nodes were removed and lymph node (LN) cells cultured for 72 hours with media, 100pg/ml IMM-101 , 10pg/ml P. acnes or 16.67pg/ml plate bound anti-CD3.
- LN lymph node
- CD3 is a co-receptor that helps activate T-cells.
- Both P.acnes and IMM-101 during the challenge phase of the experiment act as surrogates for a number of TAAs, by virtue of the sequence homology shared between multiple TAAs and endogenous P.acnes and IMM-101 genes.
- Supernatants were collected and cytokine (Figure 4b - IFN- ⁇ and IL-17) levels in culture supernatants were determined by ELISA ( ⁇ SEM). (* p ⁇ 0.05, ** p ⁇ 0.01 , *** p ⁇ 0.001).
- CDK4 is not a solid criterion for discriminating between tumor and healthy pancreatic tissues.
- HER-2/neu is expressed in human renal cell carcinoma at heterogeneous levels independently of tumor grading and staging and can be recognized by HLA-A2.1 -restricted cytotoxic T lymphocytes. Int. J. Cancer. 87: 349.
- RNA interference suppression of mucin 5AC reduces the adhesive and invasive capacity of human pancreatic cancer cells. J. Exp. Clin. Cancer Res. 29: 53.
- WT1 Wilms' tumor protein 1
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Toxicology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention resides in the preparation of a medicament to aid in the treatment of cancer. According to the invention, there is a non-viable whole cell Mycobacterium for use in the treatment of a cancer in combination with a tumour associated antigen (TAA), wherein the cancer is characterised by the presence of the TAA.
Description
IMMUNOTHERAPEUTIC TREATMENT OF CANCER
FIELD OF THE INVENTION The present invention relates to the field of cancer therapy. In particular, the present invention relates to a method of preventing, treating or inhibiting the development of tumours and/or metastases in a subject.
BACKGROUND OF THE INVENTION
In humans with advanced cancer, anti-tumour immunity becomes ineffective due to the tightly regulated interplay of pro- and anti-inflammatory, immune- stimulatory and immunosuppressive signals. For example, loss of the antiinflammatory signals leads to chronic inflammation and prolonged proliferative signalling. Interestingly, cytokines that both promote and suppress proliferation of the tumour cells are produced at the tumour site. It is the imbalance between the effects of these various processes that results in tumour promotion.
To date, a major barrier to attempts to develop effective immunotherapy for cancer has been an inability to break immunosuppression at the cancer site and restore normal networks of immune reactivity. The physiological approach of immunotherapy is to normalize the immune reactivity so that, for example, the endogenous tumour antigens would be recognized and effective cytolytic responses would be developed against tumour cells. Although it was once unclear if tumour immunosurveillance existed, it is now believed that the immune system constantly monitors and eliminates newly transformed cells. Accordingly, cancer cells may alter their phenotype in response to immune pressure in order to escape attack (immunoediting) and upregulate expression of inhibitory signals. Through immunoediting and other subversive processes, primary tumour and metastasis maintain their own survival.
Tumour associated antigens (TAAs) can be recognised by autologous antibodies and T cells and are capable of inducing tumour-directed immune responses.
Many TAAs are now potential targets for immunotherapies, being prepared as part of a "cancer vaccine".
However, producing effective treatment vaccines has proven to be challenging. To be effective, cancer treatment vaccines must achieve two goals. First, they must stimulate specific immune responses against the correct target and, second, the immune responses must be powerful enough to overcome the barriers that cancer cells use to protect themselves from attack by immune cells. In the context of therapy based on administration of TAAs, there is a problem in that TAAs are often at the core self-antigens, so the immune system is geared towards not responding to them. Therefore, there can be a lack of effective targeting to dendritic cells and consequently a lack of induction of effective anti- tumour Type 1 responses.
There is therefore a need for improved cancer vaccine therapy aimed at TAA. SUMMARY OF THE INVENTION The present inventors have identified that there is significant genetic sequence homology between the sequences of a number of relevant and common TAAs and sequences present in the genome of mycobacteria, particularly M. obuense (NCTC13365) and M. vaccae (NCTC1 1695). This genetic similarity can be exploited to provide a therapy for patients suffering from a neoplastic disorder characterised by the presence of endogenous TAAs corresponding to those intended for administration.
The present invention provides an effective method for treating and/or preventing cancer and/or the establishment of metastases by administering selective tumour associated antigens together with a whole cell Mycobacterium.
In a first aspect of the invention, there is a non-viable whole cell Mycobacterium and a tumour associated antigen (TAA) as a combined preparation for
simultaneous, separate, or sequential use in the treatment of a neoplastic disease.
In a second aspect of the invention, there is a method of treating, reducing, inhibiting or controlling a neoplastic disorder in a subject, wherein said method comprises simultaneously, separately or sequentially administering a method for treating a neoplastic disorder in a patient, comprising administering to the patient a non-viable whole cell Mycobacterium and one or more tumour associated antigens, wherein the disorder is characterised by the presence of said one or more antigens, and wherein the antigen(s) to be administered to the patient have genetic homology to exogenous sequences in said Mycobacterium.
In a third aspect of the invention, there is a non-viable Mycobacterium for therapeutic use in priming dendritic cells in a patient suffering a neoplastic disorder, wherein the Mycobacterium is M. obuense (IMM-101 ) and the disorder is characterised by the presence of one or more of the following tumour associate antigens: ERBB2, CDK4, RASK, WTIP, CDC27, MAGEA1 , MUC5AC, TP53, or CSAG2. In a fourth aspect of the invention, there is a non-viable Mycobacterium for therapeutic use in priming dendritic cells in a patient suffering a neoplastic disorder, wherein the Mycobacterium is M. vaccae (NCTC1 1695) and the disorder is characterised by the presence of one or more of the following tumour associated antigens: CDK4, ERBB2, RASK, PTPRC, GAGE7, MUC5A, GAGE2b, TP53, GAGE2a, CDC27, MSLN, MAGEA1 , MUC16, REC04, or SSX2.
The present invention therefore provides a combination therapy of specific tumour associated antigens together with a specific Mycobacterium. The inventors have found that the combination of both therapies has benefits over the administration of TAAs only.
Description of the Drawings
The invention is described with reference to the following drawings, in which: Figure 1 illustrates overall survival Kaplan-Meier Curves for the Intention to Treat (ITT) population in an all patient (a) and a metastatic subgroup (b), shows significant effect of IMM-101 (M. obuense) treatment (0.1 mL intradermal injection of 10mg/ml_) in combination with gemcitabine (1000mg/m2) in the metastatic group (p= 0.01 1) compared to control (Gemcitabine alone) and a trend towards protection in all patients (p= 0.075). Survival Probability at 12, 18 and 24 months for ITT population ±SEM is shown for the all patient group (c) and metastatic subgroup (d).
Figure 2 illustrates (A) Flow cytometric analysis of the activation/maturation or (B) ELISA of cell culture supernatants from murine GMCSF bone marrow derived DCs following overnight stimulation with 10, 100 or 300pg/ml IMM-101 ,
PBS, 250g/ml LPS or 250pg/ml Pam3Cys (Data combined from 3 experiments).
(C) Flow cytometric analysis or of the activation/maturation or (D) CBA analysis of culture supernatants from human monocyte derived DCs following overnight culture with 10, 100 or 300 g/ml IMM-101 , PBS, or 250ng/ml LPS (one example donor from 2 repeats). (* p<0.05, ** p<0.01 , *** p<0.001 ). This shows the ability of M. obuense (IMM101 ) to prime dendritic cells.
Figure 3 illustrates CFSE-labeled OVA specific OTII CD4+ T cells were cultured for 72 hours alone (T cells'), with murine GMCSF bone marrow derived DCs that had been pre-exposed to IMM-101 (ΊΜΜ'), or with control, non-exposed DCs ('Media'), with the addition of OVA peptide (0.01 pg/ml) or OVA protein (5 pg/ml). (A) Flow cytometric histograms showing cell proliferation CFSE dilution in OTII T cells and (B) the percentage of T cells in each proliferation peak (±SEM). This shows the ability of M. obuense (IMM101) to effectively prime dendritic cells and the positive effect on presentation to CD4+ cells.
Figure 4 illustrates (A) Mice were injected s.c. with IMM-101 -activated or control (media) GMCSF bone marrow derived DCs or Propionibacterium acnes (P.acnes)-activated GMGSF bone marrow-derived DCs. 7 days later, draining lymph nodes were removed, and lymph node (LN) cells cultured for 72 hours with media, 100pg/ml IMM-101 , 10pg/ml P. acnes or 16.67pg/ml plate bound anti-CD3. (B) Cytokine levels in culture supernatants were determined by ELISA (±SEM). (* p<0.05, ** p<0.01 , *** p<0.001).
Detailed Description of the Invention
The present invention provides an effective means to treat neoplastic disorders with immunotherapy. The realisation that mycobacteria share sequence homology with certain TAAs allows the mycobacteria to be utilised in therapies designed to treat neoplastic disorders using TAAs. The mycobacteria are shown to activate dendritic cells for effective antigen presentation and help provide a powerful immune response to overcome the barriers that cancer cells use to protect against attack by immune cells such as cytotoxic T cells, natural killer cells and macrophages. In order that the present invention may be more readily understood, certain terms are first defined. Additional definitions are set forth throughout the detailed description.
The terms "tumour," "cancer" and "neoplasia" are used interchangeably and refer to a cell or population of cells whose growth, proliferation or survival is greater than growth, proliferation or survival of a normal counterpart cell, e.g. a cell proliferative or differentiative disorder. Typically, the growth is uncontrolled. The term "malignancy" refers to invasion of nearby tissue. The term "metastasis" refers to spread or dissemination of a tumour, cancer or neoplasia to other sites, locations or regions within the subject, in which the sites, locations or regions are distinct from the primary tumour or cancer.
The term "therapeutically effective amount" is defined as an amount of a TAA, in combination with a Mycobacterium, that preferably results in a decrease in severity of disease symptoms, an increase in frequency and duration of disease symptom-free periods, or a prevention of impairment or disability due to the disease affliction. The terms "effective amount" or "pharmaceutically effective amount" refer to a sufficient amount of an agent to provide the desired biological or therapeutic result. That result can be reduction, amelioration, palliation, lessening, delaying, and/or alleviation of one or more of the signs, symptoms, or causes of a disease, or any other desired alteration of a biological system. In reference to cancer, an effective amount may comprise an amount sufficient to cause a tumour to shrink and/or to decrease the growth rate of the tumour (such as to suppress tumour growth) or to prevent or delay other unwanted cell proliferation. In some embodiments, an effective amount is an amount sufficient to delay development, or induce stabilisation of the cancer or tumour. It may also prolong survival.
In some embodiments, a therapeutically effective amount is an amount sufficient to prevent or delay recurrence. A therapeutically effective amount can be administered in one or more administrations. The therapeutically effective amount of the therapeutic preparation or preparations may result in one or more of the following: (i) reduce the number of cancer cells; (ii) reduce tumour size; (iii) inhibit, retard, slow to some extent and preferably stop cancer cell infiltration into peripheral organs; (iv) inhibit (i.e., slow to some extent and preferably stop) tumour metastasis; (v) inhibit tumour growth; (vi) prevent or delay occurrence and/or recurrence of tumour; and/or (vii) relieve to some extent one or more of the symptoms associated with the cancer.
For example, for the treatment of tumours, a "therapeutically effective dosage" may induce tumour shrinkage by at least about 5 % relative to baseline measurement, such as at least about 10 %, or about 20 %, or about 60 % or more. The baseline measurement may be derived from untreated subjects.
A therapeutically effective amount of a therapeutic preparation or preparations
can decrease tumour size, or otherwise ameliorate symptoms in a subject. One of ordinary skill in the art would be able to determine such amounts based on such factors as the subject's size, the severity of the subject's symptoms, and the particular composition or route of administration selected.
The term "immune response" refers to the action of, for example, lymphocytes, antigen presenting cells, phagocytic cells, granulocytes, and soluble macromolecules produced by the above cells or the liver (including antibodies, cytokines, and complement) that results in selective damage to, destruction of, or elimination from the human body of cancerous cells.
The term "treatment" or "therapy" refers to administering an active agent with the purpose to cure, heal, alleviate, relieve, alter, remedy, ameliorate, improve, or affect a condition (e.g., a disease), the symptoms of the condition, or to prevent or delay the onset of the symptoms, complications, biochemical indicia of a disease, or otherwise arrest or inhibit further development of the disease, condition, or disorder in a statistically significant manner.
As used herein, the term "subject" is intended to include human and non- human animals. Preferred subjects include human patients in need of enhancement of an immune response. The methods are particularly suitable for treating human patients having a neoplastic disorder. In a particular embodiment, the methods are particularly suitable for treatment of cancer cells in vivo. As used herein, the terms "concurrent administration" or "concurrently" or "simultaneous", "sequential" or "separate" mean that administration of the Mycobacterium and TAA occur as part of the same treatment regimen.
"Simultaneous" administration, as defined herein, includes the administration of the Mycobacterium and one or more TAAs within about 2 hours or about 1 hour or less of each other, even more preferably at the same time.
"Separate" administration, as defined herein, includes the administration of the Mycobacterium and one or more TAAs, more than about 12 hours, or about 8 hours, or about 6 hours or about 4 hours or about 2 hours apart. "Sequential" administration, as defined herein, includes the administration of the Mycobacterium and one or more TAAs each in multiple aliquots and/or doses and/or on separate occasions. The Mycobacterium may be administered to the patient after before and/or after administration of the one or more TAAs. Alternatively, the Mycobacterium is continued to be applied to the patient after treatment with the one or more TAAs.
The use of the alternative (e.g., "or") should be understood to mean either one, both, or any combination thereof of the alternatives. As used herein, the indefinite articles "a" or "an" should be understood to refer to "one or more" of any recited or enumerated component.
As used herein, "about" means within an acceptable error range for the particular value as determined by one of ordinary skill in the art, which will depend in part on how the value is measured or determined, i.e., the limitations of the measurement system. For example, "about" can mean within 1 or more than 1 standard deviation per the practice in the art. Alternatively, "about" can mean a range of up to 20%. When particular values are provided in the application and claims, unless otherwise stated, the meaning of "about" should be assumed to be within an acceptable error range for that particular value.
The Mycobacterium is non-viable, e.g. is a heat-killed Mycobacterium, preferably a whole cell Mycobacterium. Examples of mycobacterial species for use in the present invention include M. vaccae, M. thermoresistibile, M. flavescens, M. duvalii, M. phlei, M. obuense, M. parafortuitum, M. sphagni, M. aichiense, M. rhodesiae, M. neoaurum, M. chubuense, M. tokaiense, M. komossense, M. aurum, M. w, M. tuberculosis, M. microti; M. africanum; M. kansasii, M. marinum; M. simiae; M. gastri; M. nonchromogenicum; M. terrae; M. triviale; M. gordonae; M. scrofulaceum; M. paraffinicum; M. intracellulare; M. avium;
M. xenopi; M. ulcerans; M. diernhoferi, M. smegmatis; M. thamnopheos; M. flavescens; M. fortuitum; M. peregrinum; M. chelonei; M. paratuberculosis; M. leprae; M. lepraemurium and combinations thereof. Preferably, the heat-killed Mycobacterium is non-pathogenic. The nonpathogenic heat-killed Mycobacterium is preferably selected from M. vaccae, M. obuense, M. parafortuitum, M. aurum, M. indicus pranii, M. phlei and combinations thereof. More preferably the non-pathogenic heat-killed Mycobacterium is a rough variant. The amount of Mycobacterium administered to the patient is sufficient to elicit a protective immune response in the patient such that the patient's immune system is able to mount an effective immune response to the cancer or tumour. In certain embodiments of the invention, there is provided a containment means comprising the effective amount of heat-killed Mycobacterium or use in the present invention, which typically may be from 103 to 1011 organisms, preferably from 104 to 1010 organisms, more preferably from 106 to 1010 organisms, and even more preferably from 106 to 109 organisms. The effective amount of heat-killed Mycobacterium for use in the present invention may be from 103 to 1011 organisms, preferably from 104 to 1010 organisms, more preferably from 106 to 1010 organisms, and even more preferably from 106 to 109 organisms. Most preferably the amount of heat-killed Mycobacterium for use in the present invention is from 107 to 109 cells or organisms. Typically, the composition according to the present invention may be administered at a dose of from 108 to 109 cells for human and animal use. Alternatively the dose is from 0.01 mg to 1 mg or from 0.1 mg to 1 mg organisms presented as either a suspension or dry preparation.
M. vaccae and M. obuense are particularly preferred. M. obuense is sometimes referred to as IMM-101 and a suitable exemplary strain is deposited under the NCTC accession number, NCTC13365. A suitable exemplary strain of M.vaccae is deposited under the NCTC accession number NCTC1 1659.
The present invention may be used to treat a neoplastic disease, such as solid or non-solid cancers. As used herein, "treatment" encompasses the prevention,
reduction, control and/or inhibition of a neoplastic disease. Such diseases include a sarcoma, carcinoma, adenocarcinoma, melanoma, myeloma, blastoma, glioma, lymphoma or leukemia. Exemplary cancers include, for example, carcinoma, sarcoma, adenocarcinoma, melanoma, neural (blastoma, glioma), mesothelioma and reticuloendothelial, lymphatic or haematopoietic neoplastic disorders (e.g., myeloma, lymphoma or leukemia). In particular aspects, a neoplasm, tumour or cancer includes a lung adenocarcinoma, lung carcinoma, diffuse or interstitial gastric carcinoma, colon adenocarcinoma, prostate adenocarcinoma, esophagus carcinoma, breast carcinoma, pancreas adenocarcinoma, ovarian adenocarcinoma, adenocarcinoma of the adrenal gland, adenocarcinoma of the endometrium or uterine adenocarcinoma.
Neoplasia, tumours and cancers include benign, malignant, metastatic and non- metastatic types, and include any stage (I, II, III, IV or V) or grade (G1 , G2, G3, etc.) of neoplasia, tumour, or cancer, or a neoplasia, tumour, cancer or metastasis that is progressing, worsening, stabilized or in remission. Cancers that may be treated according to the invention include but are not limited to cells or neoplasms of the bladder, blood, bone, bone marrow, brain, breast, colon, esophagus, gastrointestines, gum, head, kidney, liver, lung, nasopharynx, neck, ovary, prostate, skin, stomach, testis, tongue, or uterus. In addition, the cancer may specifically be of the following histological type, though it is not limited to the following: neoplasm, malignant; carcinoma; carcinoma, undifferentiated; giant and spindle cell carcinoma; small cell carcinoma; papillary carcinoma; squamous cell carcinoma; lymphoepithelial carcinoma; basal cell carcinoma; pilomatrix carcinoma; transitional cell carcinoma; papillary transitional cell carcinoma; adenocarcinoma; gastrinoma, malignant; cholangiocarcinoma; hepatocellular carcinoma; combined hepatocellular carcinoma and cholangiocarcinoma; trabecular adenocarcinoma; adenoid cystic carcinoma; adenocarcinoma in adenomatous polyp; adenocarcinoma, familial polyposis coli; solid carcinoma; carcinoid tumour, malignant; bronchiolo-alveolar adenocarcinoma; papillary adenocarcinoma; chromophobe carcinoma; acidophil carcinoma; oxyphilic adenocarcinoma; basophil carcinoma; clear cell adenocarcinoma; granular cell carcinoma; follicular adenocarcinoma; papillary and follicular adenocarcinoma;
nonencapsulating sclerosing carcinoma; adrenal cortical carcinoma; endometroid carcinoma; skin appendage carcinoma; apocrine adenocarcinoma; sebaceous adenocarcinoma; ceruminous adenocarcinoma; mucoepidermoid carcinoma; cystadenocarcinoma; papillary cystadenocarcinoma; papillary serous cystadenocarcinoma; mucinous cystadenocarcinoma; mucinous adenocarcinoma; signet ring cell carcinoma; infiltrating duct carcinoma; medullary carcinoma; lobular carcinoma; inflammatory carcinoma; Paget's disease, mammary; acinar cell carcinoma; adenosquamous carcinoma; adenocarcinoma with squamous metaplasia; thymoma, malignant; ovarian stromal tumour, malignant; thecoma, malignant; granulosa cell tumour, malignant; androblastoma, malignant; Sertoli cell carcinoma; Leydig cell tumour, malignant; lipid cell tumour, malignant; paraganglioma, malignant; extra- mammary paraganglioma, malignant; pheochromocytoma; glomangiosarcoma; malignant melanoma; amelanotic melanoma; superficial spreading melanoma; malignant melanoma in giant pigmented nevus; epithelioid cell melanoma; blue nevus, malignant; sarcoma; fibrosarcoma; fibrous histiocytoma, malignant; myxosarcoma; liposarcoma; leiomyosarcoma; rhabdomyosarcoma; embryonal rhabdomyosarcoma; alveolar rhabdomyosarcoma; stromal sarcoma; mixed tumour; Mullerian mixed tumour; nephroblastoma; hepatoblastoma; carcinosarcoma; mesenchymoma, malignant; Brenner tumour, malignant; phyllodes tumour, malignant; synovial sarcoma; mesothelioma, malignant; dysgerminoma; embryonal carcinoma; teratoma, malignant; struma ovarii, malignant; choriocarcinoma; mesonephroma, malignant; hemangiosarcoma; hemangioendothelioma, malignant; Kaposi's sarcoma; hemangiopericytoma, malignant; lymphangiosarcoma; osteosarcoma; juxtacortical osteosarcoma; chondrosarcoma; chondroblastoma, malignant; mesenchymal chondrosarcoma; giant cell tumour of bone; Ewing's sarcoma; odontogenic tumour, malignant; ameloblastic odontosarcoma; ameloblastoma, malignant; ameloblastic fibrosarcoma; pinealoma, malignant; chordoma; glioma, malignant; ependymoma; astrocytoma; protoplasmic astrocytoma; fibrillary astrocytoma; astroblastoma; glioblastoma; oligodendroglioma; oligodendroblastoma; primitive neuroectodermal; cerebellar sarcoma; ganglioneuroblastoma; neuroblastoma; retinoblastoma; olfactory neurogenic tumour; meningioma, malignant;
neurofibrosarcoma; neurilemmoma, malignant; granular cell tumour, malignant; malignant lymphoma; Hodgkin's disease; Hodgkin's; paragranuloma; malignant lymphoma, small lymphocytic; malignant lymphoma, large cell, diffuse; malignant lymphoma, follicular; mycosis fungoides; other specified non-Hodgkin's lymphomas; malignant histiocytosis; multiple myeloma; mast cell sarcoma; immunoproliferative small intestinal disease; leukemia; lymphoid leukemia; plasma cell leukemia; erythroleukemia; lymphosarcoma cell leukemia; myeloid leukemia; basophilic leukemia; eosinophilic leukemia; monocytic leukemia; mast cell leukemia; megakaryoblastic leukemia; myeloid sarcoma; and hairy cell leukemia. Preferably, the neoplastic disease may be tumours associated with a cancer selected from prostate cancer, liver cancer, renal cancer, lung cancer, breast cancer, colorectal cancer, pancreatic cancer, brain cancer, hepatocellular cancer, lymphoma, leukaemia, gastric cancer, cervical cancer, ovarian cancer, thyroid cancer, melanoma, head and neck cancer, skin cancer and soft tissue sarcoma and/or other forms of carcinoma. The tumour may be metastatic or a malignant tumour.
More preferably, the neoplastic disease to be treated is pancreatic cancer, breast cancer, lung cancer, ovarian cancer, colorectal cancer, prostate cancer and skin cancer. In a preferred embodiment the neoplastic disease to be treated is pancreatic cancer. In a further preferred embodiment, the neoplastic disease to be treated is lung cancer. In a further preferred embodiment, the neoplastic disease to be treated is colorectal cancer. In an embodiment of the invention, the therapy is used to reduce or inhibit metastasis of a primary tumour or cancer to other sites, or the formation or establishment of metastatic tumours or cancers at other sites distal from the primary tumour or cancer, thereby inhibiting or reducing tumour or cancer relapse or tumour or cancer progression.
In further embodiments, methods of the invention include, one or more of the following: 1) reducing or inhibiting growth, proliferation, mobility or invasiveness of tumour or cancer cells that potentially or do develop metastases, 2) reducing
or inhibiting formation or establishment of metastases arising from a primary tumour or cancer to one or more other sites, locations or regions distinct from the primary tumour or cancer; 3) reducing or inhibiting growth or proliferation of a metastasis at one or more other sites, locations or regions distinct from the primary tumour or cancer after a metastasis has formed or has been established, 4) reducing or inhibiting formation or establishment of additional metastasis after the metastasis has been formed or established, 5) prolonged overall survival, 6) prolonged progression free survival, or 7) disease stabilisation.
The therapeutic effect may not take effect immediately. For example, treatment may be followed by an increase in the neoplasia, tumour or cancer cell numbers or mass, but over time eventual stabilization or reduction in tumour cell mass, size or numbers of cells in a given subject may subsequently occur.
Additional adverse symptoms and complications associated with neoplasia, tumour, cancer and metastasis that can be inhibited, reduced, decreased, delayed or prevented include, for example, nausea, lack of appetite, lethargy, pain and discomfort. Thus, a partial or complete decrease or reduction in the severity, duration or frequency of an adverse symptom or complication associated with or caused by a cellular hyperproliferative disorder, an improvement in the subjects quality of life and/or well-being, such as increased energy, appetite, psychological well-being, are all particular non-limiting examples of therapeutic benefit.
A therapeutic benefit or improvement therefore can also include a subjective improvement in the quality of life of a treated subject. In an additional embodiment, a method prolongs or extends lifespan (survival) of the subject. In a further embodiment, a method improves the quality of life of the subject.
The Mycobacterium for use according to the invention is administered in combination with one or more TAAs that share genetic sequence homology with the Mycobacterium.
The term "genetic sequence homology" is intended to mean that the sequence of a TAA is significantly similar to a genetic sequence in the Mycobacterium. The sequence similarity can be derived by carrying out a BLAST (Basic Local Alignment Search Tool) alignment and analysis between a TAA and the mycobacterial generic sequence. The BLAST method, using the BLAST software version 2.2.28 (available at www.blast.ncbi.nlm.nih.gov/Blast.cqi), using the heuristic based algorithm identifies similar sequences by locating short matches between two sequences - known as seeding, allowing identification and scoring for the significance of each alignment according to the BLAST algorithm. The BLAST algorithm locates all common sequences of interest (cased on amino acid alignment) and aligns them to a preferred database or reference sequence, e.g. the genome sequences of the Mycobacterium. The sequences identified are then used to assemble aligned sequences and identify homologous regions and scored for significance according to key criteria including e-value scores.
The parameters used to identify homologues were "stringent" parameters. This required the "alignment length" to be at least 50 base pairs (bp) and an "e-val" score to be less than 0.5.
In a preferred embodiment, the therapy comprises administration of M. obuense in combination with one or more of the TAAs identified in Table 1. Table 1 TAA with homologies to sequences in M. obuense NCTC13365.
SUBSTITUTE SHEET RULE 26
RASK GTPase KRas httD://www.Droteinatlas.ora/ENSG00000133703-
KRAS/aene
WTIP Wilms tumour http://www.uniprot.org/uniprot/A6NIX2
protein 1 - interacting protein
CDC27 Cell division cycle httD://www.Droteinatlas.ora/ENSG00000004897- protein 27 CDC27/cancer
homolog
MAGEA1 Melanoma- http://www.uniprot.org/uniprot/P43355
associated
antigen 1
MUC5A Mucin-5AC http://www.uniprot.org/uniprot/P98088
TP53 Cellular tumour httD://www.Droteinatlas.ora/ENSG00000141510- antigen p53 TP53/aene
CSAG2 Chondrosarcoma- http://www.proteinatlas.orq/ENSG00000198930- associated gene CSAG1/aene
2/3 protein
To maximize success of TAAs used in immunotherapy, target TAAs with a restricted expression pattern in normal tissues need to be identified. Ideally target TAAs should be expressed in high frequency in tumour tissue and induce strong adaptive immune responses to confirm their immunogenic potential. Here we describe in some details whether the TAA showing homologies with M. obuense NCTC13365 may offer potential as suitable immunotherapeutic targets.
CDK4
Cyclin-dependent Kinase 4 (CDK4) is a member of the Ser/Thr kinase family. The human protein shares 94% and 95% aa sequence identity with the mouse and rat orthologs, respectively. CDK4 shuttles between the cytoplasm and nucleus as part of its role in cell cycle regulation. It promotes the transition from G1 to S phase by phosphorylating and inactivating RB1. Activation of CDK4 requires binding of a D-type Cyclin and phosphorylation of Thr172 by the CAK
SUBSTITUTE SHEET RULE 26
kinase complex. Negative regulators of CDK4 are Calcineurin, p21/CIP1/CDKN1A and p27/Kip1. CDK4 inhibition decreases homologous recombination and increases non-homologous end joining, suggesting that CDK4 may also promote error free DNA repair.
CDK4s might play a significant role in malignant disease. Amplification of the CDK4 gene, located at 12q13-q14, has been found as an alternative genetic alteration to CDKN2A inactivation in various human tumors including malignant gliomas and sarcomas (An et al, 1999). A somatic point mutation (R24C) of the CDK4 gene was identified in human melanomas, causing a tumor-specific antigen and disrupting the interaction between CDK4 and its inhibitor p16 and is recognized by CD8+ cells (Wolfel et al., 1995).
CDK4 has been suggested to be a prognostic marker for hepatocellular carcinoma and its kinase activity has been reported to promote the progression of T cell acute lymphoblastic leukemia; however, CDK4 failed to discriminate between healthy and malignant pancreatic tissue (Altirriba et al., 2012).
ERBB2 (Her2/neu)
ErbB2 or Her2/neu is a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. This protein has no ligand binding domain of its own and therefore cannot bind growth factors. However, it does bind tightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways, such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. ErbB2/Her2 is considered an oncogene; it is selectively over-expressed in a broad variety of human tumors including 25-40% of breast, ovarian, gastric, renal, esophageal and colorectal carcinomas and a small proportion of human melanomas (Selinger et al., 2000; Mimura et al., 2005; Al-kuraya et al., 2007). As a cell surface molecule it is accessible both to antibody- and T cell-based approaches. Moreover, ErbB2/Her2 can be regarded as an indispensable tumor antigen, since tumors over-expressing this protein are dependent on this oncogene for their survival
and silencing consequently leads to growth arrest and/or apoptosis induction. Several groups have defined ErbB2/Her2 specific cytotoxic T lymphocytes epitopes and demonstrated that cytotoxic T lymphocytes can recognize and kill ErbB2/Her2 expressing tumors (Lollini et al., 1998; Anderson et al., 2000; Azuma et al., 2004; Kaplan et al., 2006).
Nepoletano and colleagues (2009) described the generation of an allogenic microvesicle cell factory in which the expression of a specific tumor antigen was combined to the expression of co-stimulatory and allogeneic molecules. The DG75 lymphoblastoid cell line was selected as microvesicle producer and transfected with ErbB2/Her2, as tumor antigen prototype. The shed microvesicles transferred antigenic components to recipient DCs, increasing their immunogenicity. DC pulsing resulted in cross-presentation of ErbB2/Her2 both in MHC class I and MHC class II compartments, and ErbB2/Her2-specific CD8+ T cells from cancer patients were activated by DCs pulsed with vesicle- bound ErbB2.
RASK
Mutant p21-ras proteins contain sequences that distinguish them from normal ras, and represent unique epitopes for T-cell recognition of antigen-bearing tumour cells. Gjertsen and colleagues (1997) examined the capacity of CD4+ and CD8+ T cells, generated simultaneously by mutant-ras-peptide vaccination of a pancreatic-adenocarcinoma patient, to recognize and lyse autologous tumour cells harbouring corresponding activated K-ras epitopes. The patient was vaccinated with a purified 17mer ras peptide (KLVWG AVG VG KS ALT I ) , containing the Gly12 -> Val substitution. Responding T cells were cloned following peptide stimulation, and CD4+ and CD8+ peptide-specific cytotoxic T lymphocytes were obtained. Transient pancreatic-adenocarcinoma cell lines were established in cell culture from malignant ascites of the patient, and were shown to harbour the same K-ras mutation as found in the primary tumour. These cells were efficiently killed by the T-cell clones and CD8+-mediated cytotoxicity was MHC-class-l-restricted, as demonstrated by inhibition of lysis by anti-class-l monoclonal antibodies.
WTIP
WTIP (Wilms Tumor 1 Interacting Protein) is a protein coding gene. Diseases associated with WTIP include Wlms tumour. WTIP is an adapter or scaffold protein which participates in the assembly of numerous protein complexes and is involved in several cellular processes such as cell fate determination, cytoskeletal organization, repression of gene transcription, cell-cell adhesion, cell differentiation, proliferation and migration. It also positively regulates microRNA (miRNA)-mediated gene silencing and negatively regulates Hippo signaling pathway and antagonizes phosphorylation of YAP1. It acts as a transcriptional corepressor for S NAM and SNAI2/SLUG-dependent repression of E-cadherin transcription and as a hypoxic regulator by bridging an association between the prolyl hydroxylases and VHL enabling efficient degradation of HIF1A.
There is increasing clinical evidence to suggest that WTIP may be a promising immunotherapeutic target. For example, vaccine-induced immunological responses could be detected in patients with either haematological or solid cancers. Moreover, objective responses, such as stable disease were recorded in these patients (reviewed in van Driessche et al., 2012)
CDC27
The protein encoded by this gene shares strong similarity with Saccharomyces cerevisiae protein Cdc27, and the gene product of Schizosaccharomyces pombe nuc 2. This protein is a component of the anaphase-promoting complex (APC), which is composed of eight protein subunits and is highly conserved in eukaryotic cells. This complex catalyzes the formation of cyclin B-ubiquitin conjugate, which is responsible for the ubiquitin-mediated proteolysis of B-type cyclins. The protein encoded by this gene and three other members of the APC complex contain tetratricopeptide (TPR) repeats, which are important for protein- protein interactions. This protein was shown to interact with mitotic checkpoint proteins including Mad2, p55CDC and BUBR1 , and it may thus be involved in controlling the timing of mitosis.
A mutation in CDC27 causing altered protein trafficking into the endosomal compartment was found in a melanoma. This allows for the presentation of an MHC class II epitope and recognition by CD4+ cells (Wang et al., 1999).
MAGE A1
The Melanoma Antigen Gene (MAGE) family, classified as cancer-testis antigens (CTA) is a large family of over 40 proteins usually expressed in the testis, but it can be found to be expressed in a number of tumours such as breast, ovary, lung, and bladder (Weon and Potts, 2015). This abnormal expression may be the result of the activation of a silent "gametogenic program", which is involved in tumour progression. In the case of MAGE-A, expression appears to be specifically related to a malignant phenotype, characterized by invasiveness and metastasis, and is often associated with poor prognosis in patients. Studies have suggested that these proteins may effect transcriptional repressor proteins, promoting tumour survival by supressing p53, which is involved in apoptosis and senescence (Meek and Marcar, 2012; Weon and Potts, 2015). However, MAGE-A are also broadly immunogenic and for this reason offer potential in cancer immunotherapy (Daudi et al., 2014). MAGE proteins have received increased attention in recent years as immunotherapeutic targets. Whereas a large Phase III trial in lung cancer (MAGRIT) has failed to show a therapeutic effect of targeting MAGE-A3 as measured by increase in disease-free survival vs placebo, the potential remains with alternative drug combinations and approaches (Ruiz et al., 2014).
MUC5AC
MUC5AC is a member of the mucin family, and as such expressed in mucotic tissue including the lung, the gastrointestinal tract and the pancreas. The mucin family consists of a heterogeneous group of 21 high molecular weight O- glycoproteins that can be either secreted or are membrane bound. Mucins, in particular MUC1 have been used in TAA cancer vaccines, more than 60 clinical trials are in progress and three have reached phase IIB/III; BLP25 a lyposomal vaccine, TG4010 which uses a recombinant modified vaccinia Ankara virus and
an oxidized mannan MUC1 (reviewed in Roulois et al., 2013). MUC5AC could also become a relevant immunotherapeutic target. In the case of pancreatic cancer, MUC5A is not expressed in healthy tissue but is detected in precursor neoplastic lesions and in tumour tissue (Kim et al., 2002). Interestingly, it has been suggested that MUC5AC accelerates progression of pancreatic cancer adenocarcinoma and at least in vitro its inhibition reduces invasiveness (Yamazoe et al. 2010). In two phase I trial, treatment with mAbs targeting MUC5AC (NEO-101 ) showed therapeutic activity, with patients remaining stable and reaching greater than 12 months survival after having progressed on standard therapy (Morse et al., 2012; Patel et al., 2014). Based on these initial results, a phase II study of NEO-102 given in combination with gemcitabine is on-going in patients with refractory pancreatic cancer.
TP53
The TP53 is a tumour suppressor gene. The p53 protein binds DNA and induces production of p21 which when complexed to cdk2 prevents cells from undergoing cell division. Mutations in p53 interfere with the DNA binding step so that p21 is no longer produced and cells are allowed to divide uncontrollably. Approximately 50% of all tumours exhibit mutations and overexpression of p53, making this protein an interesting candidate target for immunotherapy of cancer. Early preclinical studies have shown that adoptive transfer of p53-specific cytotoxic T cells was able to eradicate tumours overexpressing p53 (Vierboom et al., 1997). Despite deletion of p53+ self-reactive T cells, responses to p53 have been detected in humans (Houbiers et al., 1997; Chikamatsu et al., 2003). A number of phase I and II clinical trials targeting p53 have been conducted between 2002 and 2010) using viral vector-based vaccines, dendritic cell-based vaccines and peptide-based vaccines, but with limited success to date (reviewed in Vermeij et al., 201 1). Despite the disappointing results, the rationale for targeting p53 is sound. Alternative approaches aimed at increasing immunogenicity, disrupting immunoregulatory process, providing additional TAA targets, may ultimately enhance therapeutic benefit of this strategy through the development of effective anti-tumour responses.
CSAG2
Chondrosarcoma-associated gene 2/3 protein, also known as Taxol-resistant associated gene-3, belongs to the cancer testis antigen family. It appears to be associated with neoplastic phenotype and with resistance to chemotherapeutic agents. There is not as much known about this TAA compared to others listed in Table 1 , but studies investigating gene expression profiling in cancer patients and expression in cancer cell lines and biopsy specimens has identified CSAG2 in a variety of cancers including melanoma, ovarian, bladder and prostate cancer as worthy of consideration as potential immunotherapy target antigen (Karam et al., 201 1 ; Beard et al., 2013; Takahashi et al., 2015). Interestingly, spontaneous CD4+ T cell responses against CSAG2/TRAG-3 have been reported in patients with advanced melanoma and breast cancer. These patients developed IFN-g producing CD4+ T cell responses against a single immunodominant and promiscous epitope, suggesting this could be a good candidate for monitoring patients responses and for the development of immunotherapy to CTA expressing tumours (Janjic B et al., 2006).
In another preferred embodiment, the therapy comprises the administration of M. vaccae in combination with one or more of the TAAs identified in Table 2.
Table 2 TAA with homologies to sequences in M. vaccae NCTC11659.
The term "combination" as used throughout the specification, is meant to encompass the administration of the Mycobacterium simultaneously, separately or sequentially with administration of the TAA. Accordingly, the TAA and the Mycobacterium may be present in the same or separate pharmaceutical formulations, and administered at the same time or at different times.
Thus, a Mycobacterium and the TAA may be provided as separate medicaments for administration at the same time or at different times.
Preferably, a Mycobacterium and TAA are provided as separate medicaments for administration at different times. When administered separately and at different times, either the Mycobacterium or TAA may be administered first; however, it is suitable to administer the Mycobacterium followed by the TAA. In addition, both can be administered on the same day or at different days, and they can be administered using the same schedule or at different schedules during the treatment cycle.
In an embodiment of the invention, a treatment cycle consists of the administration of a Mycobacterium daily, weekly, fortnightly or monthly, simultaneously with TAA weekly. Alternatively, the Mycobacterium is administered before and/or after the administration of the TAA.
SUBSTITUTE SHEET RULE 26
Dose delays and/ or dose reductions and schedule adjustments are performed as needed depending on individual patient tolerance to treatments.
Alternatively, the administration of TAA may be performed simultaneously with the administration of the effective amounts of the Mycobacterium.
The whole cell heat-killed Mycobacterium, may be administered to the patient via the parenteral, intratumoral, oral, sublingual, nasal or pulmonary route. In a preferred embodiment, it is administered via a parenteral route selected from subcutaneous, intradermal, subdermal, intraperitoneal, intravenous and intravesicular injection. More preferably, administration comprises intratumoural injection of the mycobacterial preparation.
In an aspect of the invention, the effective amount of the Mycobacterium may be administered as a single dose. Alternatively, the effective amount of the Mycobacterium may be administered in multiple (repeat) doses, for example two or more, three or more, four or more, five or more, ten or more, or twenty or more repeat doses. The Mycobacterium may be administered between about 4 weeks and about 1 day prior to TAA therapy, such as between about 4 weeks and 1 week, or about between 3 weeks and 1 week, or about between 3 weeks and 2 weeks. Administration may be presented in single or multiple doses.
In another preferred embodiment of the invention there is a non-viable Mycobacterium for therapeutic use in priming dendritic cells in a patient suffering a neoplastic disorder, wherein the Mycobacterium is M. obuense (I MM 1 -01 ) and the disorder is characterised by the presence of one or more of the following tumour associate antigens (TAAs): ERB2, CDK4, RASK, WTIP, CDC27, MAGEA1 , MUC5AC, TP53, or CSAG2. In another preferred embodiment of the invention there is a non-viable Mycobacterium for therapeutic use in priming dendritic cells in a patient suffering a neoplastic disorder, wherein the Mycobacterium is M. vaccae and the disorder is characterised by the presence of one or more of the following tumour
associated antigens: CDK4, ERBB2, RASK, PTPRC, GAGE7, MUC5A, GAGE2b, TP53, GAGE2a, CDC27, MSLN, MAGEA1 , MUC16, REC04, or SSX2.
In another preferred embodiment of the invention there is a method of treating a neoplastic disorder in a patient, comprising administering to the patient a nonviable whole cell Mycobacterium and one or more tumour associated antigens (TAAs), wherein the disorder is characterised by the presence of said one or more antigens, and wherein the antigen(s) to be administered to the patient have genetic homology to exogenous sequences in said Mycobacterium.
Mycobacterial compositions according to the invention will comprise an effective amount of mycobacteria typically dispersed in a pharmaceutically acceptable carrier. The phrases "pharmaceutically or pharmacologically acceptable" refers to molecular entities and compositions that do not produce an adverse, allergic or other untoward reaction when administered to an animal, such as, for example, a human, as appropriate. The preparation of an pharmaceutical composition that contains mycobacteria will be known to those of skill in the art in light of the present disclosure, as exemplified by Remington's Pharmaceutical Sciences, 18th Ed. Mack Printing Company, 1990, Moreover, for animal (e.g., human) administration, it will be understood that preparations should meet sterility, pyrogenicity, general safety and purity standards. A specific example of a pharmacologically acceptable carrier as described herein is borate buffer or sterile saline solution (0.9% NaCI). As used herein, "pharmaceutically acceptable carrier" includes any and all solvents, dispersion media, coatings, surfactants, antioxidants, preservatives e.g., antibacterial agents, antifungal agents), isotonic agents, absorption delaying agents, salts, preservatives, drugs, drug stabilizers, gels, binders, excipients, disintegration agents, lubricants, sweetening agents, flavouring agents, dyes, such like materials and combinations thereof, as would be known to one of ordinary skill in the art (see, for example, Remington's Pharmaceutical Sciences, 18th Ed. Mack Printing Company, 1990, pp. 1289-1329).
The invention is further illustrated by way of the following examples Example 1
Determination of sequence homology between M.obuense and TAAs
Data obtained from whole genome sequence analysis of the extracted and purified M. obuense NCTC 13365 DNA was subjected to Basic Local Alignment Search Tool (BLAST) alignment and analysis against the selected human TAA sequences. The BLAST method, using the heuristic based algorithm identifies similar sequences by locating short matches between the two sequences - known as seeding, allowing for the identification and scoring for the significance of each alignment according to the BLAST algorithm.
The BLAST algorithm locates all common sequences of interest (based on amino acid alignment) and aligns them to a preferred database or reference sequence - in this case the genome sequences of M. obuense NCTC13365. The sequences identified are then used to assemble aligned sequences and identify homologous regions and scored for significance according key criteria including e-value scores. Given the nature of human to Mycobacterium BLAST (amino acid based) alignment, key criteria were determined to improve the significance of the homologies identified. These included requiring an alignment length of at least 50bp and an "e-val" score as close as possible to 0, so only "e- val" score less than 0.5 were taken. A total of 218 sequences were blasted onto M. obuense NCTC13365. After applying the strict selection criteria outlined above, a total of nine TAA genes were identified showing homologies with sequences in M. obuense NCTC13365. These are listed in Table 1. The raw data resulting from the search is shown in Table 3.
Table 3. TAAs with sequence homology to sequences in M.obuense NCTC13365.
Example 2
Determination of differential survival characteristics of cancer patients administered gemcitabine in combination with IMM-101 or in isolation
Patients were recruited to a multicentre (5 countries, 22 sites) randomised, open-label, proof-of-concept, Phase II Trial comparing gemcitabine (GEM) with and without M. obuense (referred to herein as IMM-101) in advanced pancreatic cancer. Patients with a WHO score of 0-2 were assigned randomly to receive IMM-101 (0.1 ml_ intradermal injection of 10 mg/mL) plus Gem (1000 mg/m2 for 3 consecutive weeks out of 4) or Gem alone. Per protocol, this regimen could be continued to a 12-cycle maximum. The primary efficacy endpoint was overall survival (OS). Safety, tolerability and progression free survival (PFS) were also assessed. A total of 1 10 patients were randomized, 75 to receive IMM-101 plus Gem and 35 Gem alone (ITT population) (Figure 1a and b). In the pre-defined sub-group of patients with metastatic disease (n=82), 64 patients received IMM- 101 plus Gem compared to 28 in the Gem group alone (Figure 1 c and d).
These studies show increased survival characteristics in both the all patent and metastatic subgroups who are co-administered IMM-101 alongside Gem.
The effect of IMM-101 on the immune system
Next the effects of IMM-101 on dendritic cell activation were assessed in order to determine whether IMM-101 enhances therapeutic efficacy by priming the immune system against recognition of tumour associated antigens (TAAs).
To assess the effects of IMM-101 on the immune system, mouse bone marrow- derived dendritic cells (BMDCs) were obtained from single cell suspensions of mouse femours and cultured in petri dishes with GM-CSF for 10 days, which included three regularly spaced media changes. Mouse BMDCs cells were then harvested and incubated overnight with 10 pg/ml, 100 pg/ml, or 300 pg/ml IMM- 101 , LPS, Pam3 or control (1 x phosphate buffered saline). Mouse peripheral
blood mononuclear cells (PBMCs) were then further harvested and phenotypic activation was assessed by FACS analysis (Figure 2a - CD40, CD83 and CD86). Supernatants from mouse PBMCs were also removed and analysed for the cytokine secretion profile by FACS (Figure 2b— IL12 and IL6).
Similar experiments were repeated in human monocyte-derived DCs (HMDCs). HMDCs were obtained from 10ml apheresis cones of healthy patients, following CD14+ selection of peripheral blood mononuclear cells (PBMCs) and cultured in the presence of IL-4 and GM-CSF for 6 days. HMDCs were harvested and phenotypic activation in the presence of 10 pg/ml, 100 pg/ml, or 300 pg/ml IMM- 101 , LPS, or control (1 x phosphate buffered saline) were assessed by FACS (CD80 and CD86). Supernatants were removed and cytokine secretion levels were measured by ELISA (Figure 2d - IL-6 and IL-12p40). The results demonstrate that incubating either mouse or human DCs with IMM-101 causes De activation.
To determine whether IMM-101 activation of DCs enhances the humoural immune response, BMDCs were pre-pulsed with IMM-101 and added to cultures of CD4+ T cells isolated from the lymph nodes and spleens of transgenic OTII mice stimulated with ovalbumin (Ova) peptide or Ova protein. Ovalbumin is a mildly immunogenic glycoprotein that is often used as a key reference protein in vaccine-based experiments. The experiments were performed alongside a control with non-exposed DCs (Media), or T-cells cultured alone. The co- cultures were incubated for 72 hours. T cells in culture were stained with CFSE to assess proliferation via flow cytometry. (Figure 3).
The CD4+ T cells of OTII mice all express transgenic Ova-specific CD4+-T cell receptors. CFSE staining allows for the number of divisions of the T cell populations to be quantified as the dye dilutes with each division. The data suggest that IMM-101 influences bacterial uptake and/or processing, as evidenced by the increased number of divisions of CFSE-stained T-cells upon incubation with OVA protein in the presence of IMM-101 -activated DCs, versus control (Figure 3). This shows the ability of IMM-101 to effectively prime
dendritic cells, with a positive effect on the presentation of antigens to CD4+ cells.
IMM-101 -primed DCs can activate the immune system against TAAs
Next, the inventors sought to determine whether IMM-101 could prime DCs to increase the recognition of TAAs. A pictorial representation of the protocol is presented in Figure 4A. Briefly, mice were injected subcutaneously in the footpad with IMM-101 -primed or control (Media) GMCSF bone marrow-derived DCs. Media DCs were not primed with IMM-101. As a control, the experiment was performed alongside P.acnes-stimulated DCs. Seven days later, popliteal draining lymph nodes were removed and lymph node (LN) cells cultured for 72 hours with media, 100pg/ml IMM-101 , 10pg/ml P. acnes or 16.67pg/ml plate bound anti-CD3. CD3 is a co-receptor that helps activate T-cells. Both P.acnes and IMM-101 during the challenge phase of the experiment (post-harvest in the experimental scheme presented in Figure 4a) act as surrogates for a number of TAAs, by virtue of the sequence homology shared between multiple TAAs and endogenous P.acnes and IMM-101 genes. Supernatants were collected and cytokine (Figure 4b - IFN-γ and IL-17) levels in culture supernatants were determined by ELISA (±SEM). (* p<0.05, ** p<0.01 , *** p<0.001).
The results show that IMM-101 -primed DCs show increased activation against both IMM-101 and P.acnes, compared to both media and P. acnes-activated DCs.
REFERENCES
Al-Kuraya K, Novotny H, Bavi P, et al. 2007. HER2, TOP2A, CCND1 , EGFR and C-MYC oncogene amplification in colorectal cancer. J. Clin. Pathol. 60: 768.
• Altirriba J, Garcia A, Sanchez B, et al. 2012. The sole presence of CDK4 is not a solid criterion for discriminating between tumor and healthy pancreatic tissues.
Int. J. Cancer. 130: 2743.
• An HX. 1999. Gene amplification and overexpression of CDK4 in sporadic breast carcinomas is associated with high tumor cell proliferation. Am. J. Pathol. 154: 1 13.
· Anderson BW, Peoples GE, Murray JL, et al. 2000. Peptide priming of cytolytic activity to HER-2 epitope 369-377 in healthy individuals. Clin. Cancer Res. 6: 4192.
• Azuma K, Shichijo S, Shomura H, et al. 2004. Identification of HER2/ neu- derived peptides capable of inducing both cellular and humoral immune responses in HLA-A24 positive breast cancer patients. Breast Cancer Res. Treat. 86: 19.
• Beard RE, Abate-Daga D, Rosati SF, et al. 2013. Gene expression profiling using nanostring digital RNA counting to identify potential target antigens for melanoma immunotherapy. Clin. Cancer Res. 19: 4941.
• Chikamatsu K, Albers A, Stanson J et al. 2003. p53-specific human CD4+ T- helper cells enhance in vitro generation and antitumor function of tumor-reactive
CD8+ T cells. Cancer Res. 63: 3675.
• Daudi S, Eng KH, Mhawech-Fauceglia P, et al. 2014. Expression and immune responses to MAGE antigens predict survival in epithelial ovarian cancer. PLoS One. 9:e104099.
· Glertsen K, BiomesOiJ, Saeterdal M^i A, Q IBS G, 1997. Cytotoxic CD4+ and CD8+ T lymphocytes, generated by mutant p21-ras (12Val) peptide vaccination of a patient, recognize 12Val-dependent nested epitopes present within the vaccine peptide and kill autologous tumour cells carrying this mutation. Int. J. Cancer. 72: 784.
· Houbiers JGA, Nijman HW, Van Der Burg SH et al. 1993. In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53. Eur. J. Immunol. 23: 2072.
• Janjic B, Andrade P and Wang X-F et al. 2006. Spontaneous CD4+ T Cell Responses against TRAG-3 in Patients with Melanoma and Breast Cancers. J. Immunol. 177: 2717.
• Kaplan BL, Norell H, Callender GG, et al. 2006. Interferon-gamma renders tumors that express low levels of Her-2/neu sensitive to cytotoxic T cells. Cancer Immunol. Immunother. 55: 653.
• Karam JA, Huang S, Fan J et al. 201 1. Upregulation of TRAG3 gene in urothelial carcinoma of the bladder. Int. J. Cancer 128: 2823.
• Kim GE, Bae HI, Park HU, et al. 2002. Aberrant expression of MUC5AC and MUC6 gastric mucins and sialyl Tn antigen in intraepithelial neoplasms of the pancreas. Gastroenterology. 123: 1052.
• Lollini PL, Nicoletti G, Landuzzi L, et al. 1998. Down regulation of major histocompatibility complex class I expression in mammary carcinoma of HER-2/neu transgenic mice. Int. J. Cancer 77: 937.
• Napoletano C, Rughetti A, Landi R, et al. 2009. Immunogenicity of allo- vesicle carrying ERBB2 tumor antigen for dendritic cell-based anti-tumor immunotherapy. Int J Immunopathol Pharmacol. 22: 647.
• Mimura K, Kono K, Hanawa M, et al. 2005. Frequencies of HER-2/neu expression and gene amplification in patients with oesophageal squamous cell carcinoma. Br. J. Cancer. 92: 1253.
· Meek DW and Marcar L. 2012. MAGE-A antigens as targets in tumour therapy. Cancer Lett. 324: 126.
• Morse M, Diaz LA, Azad NS, et al. 2012. A phase Ib/lla study of NEO-102: A therapeutic antibody to treat pancreatic and colorectal cancers. J. Clin. Oncol. 30: 233.
· Patel SP, Morse M, Shaalan Beg M et al. 2014. A Phase Ib/lla Study of NEO-102: A Therapeutic Antibody to Treat Pancreatic and Colorectal Cancers (Abstract #243). J. Clin. Oncol. 32: 243.
• Roulois D, Gregoire M and Fonteneau J-F. 2013. MUC1-Specific Cytotoxic T Lymphocytes in Cancer Therapy: Induction and Challenge. Biomed Res Int. 2013: 871936.
• Ruiz R, Hunis B and Raez LE. 2014. Immunotherapeutic agents in non- small-cell lung cancer finally coming to the front lines. Curr. Oncol. Rep. 16: 400.
• Seliger B, Rongcun Y, Atkins D, et al. 2000. HER-2/neu is expressed in human renal cell carcinoma at heterogeneous levels independently of tumor grading and staging and can be recognized by HLA-A2.1 -restricted cytotoxic T lymphocytes. Int. J. Cancer. 87: 349.
• Takahashi S, Shiraishi T, Miles N, et al. 2015. Nanowire Analysis of Cancer- Testis Antigens as Biomarkers of Aggressive Prostate Cancer. Urology. 85: 704.
• Yamazoe S, Tanaka H, Sawada, T et al. 2010. RNA interference suppression of mucin 5AC (MUC5AC) reduces the adhesive and invasive capacity of human pancreatic cancer cells. J. Exp. Clin. Cancer Res. 29: 53.
• Van Driessche A, Berneman ZN, Van Tendeloo VF. 2012. Active specific immunotherapy targeting the Wilms' tumor protein 1 (WT1) for patients with hematological malignancies and solid tumors: lessons from early clinical trials. Oncologist. 17: 250.
• Vierboom MPM, Nijman HW, Offringa R. et al. 1997. Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes," J. Exp. Med. 186: 695.
• Wang RF, Wang X, Atwood AC, Topailan SL, Rosenberg SA. 1999. Cloning genes encoding MHC class ll-restricted antigens: mutated CDC27 as a tumor antigen. Science. 284: 1351.
• Weon JL and Potts PR. 2015. The MAGE protein family and cancer. Curr. Op. Cell Bio. 37: 1.
• Wolfel T, Hauer M, Schneider J, et al. 1995. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science. 269: 1281.
Claims
1. A non-viable whole cell Mycobacterium and a tumour associated antigen (TAA) as a combined preparation for simultaneous, separate, or sequential use in the treatment of a neoplastic disease.
2. A preparation for use according to claim 1 , wherein the Mycobacterium is heat-inactivated M.obuense (IMM-101 ).
3. A preparation for use according to claim 1 or claim 2, wherein the tumour associated antigen (TAA) is a tumour antigen with genetic homology to M.obuense sequences.
4. A preparation for use according to claim 3, wherein the TAA is or is derived from one or more of ERBB2, CDK4, RASK, WTIP, CDC27, MAGEA1 ,
MUC5AC, TP53 or CSAG2.
5. A preparation according to any preceding claim, wherein the neoplastic disease is any which is characterised by the presence of any combination of the following TAAs:
ERB2, CDK4, RASK, WTIP, CDC27, MAGEA1 , MUC5AC, TP53, or CSAG2.
6. A preparation according to claim 1 , wherein the Mycobacterium is M. vaccae.
7. A preparation according to claim 6, wherein the TAA is, or is derived from, one or more of:
CDK4, ERBB2, RASK, PTPRC, GAGE7, MUC5A, GAGE2b, TP53, GAGE2a, CDC27, MSLN, MAGEA1 , MUC16, REC04, or SSX2.
8. A preparation according to claim 7 or claim 8, wherein the neoplastic disease is any which is characterised by the presence of any combination of the following TAAs:
CDK4, ERBB2, RASK, PTPRC, GAGE7, MUC5A, GAGE2b, TP53, GAGE2a, CDC27, MSLN, MAGEA1 , MUC16, REC04, or SSX2.
9. A preparation for use according to any preceding claim, wherein the Mycobacterium is administered up to 14 days prior to the administration of the TAA.
10. A preparation for use according to any preceding claim, wherein the combined preparation is administered in repeat doses.
11. A preparation for use according to any preceding claim, wherein the Mycobacterium and TAA are administered simultaneously.
12. A preparation for use according to any preceding claim, wherein the Mycobacterium is present in a unit dose comprising an effective amount of from 107 to 109 cells.
13. A preparation for use according to any preceding claim, wherein the Mycobacterium is for administration via the parenteral, intratumoral oral, sublingual, nasal, or pulmonary route.
14. A preparation for use according to claim 13, wherein parenteral route is selected from subcutaneous, intradermal, subdermal, intraperitonal, intravenous, or intravesicular injection.
15. A preparation for use according to claim 14, wherein the Mycobacterium is for intradermal administration.
16. A non-viable Mycobacterium for therapeutic use in priming dendritic cells in a patient suffering a neoplastic disorder, wherein the Mycobacterium is M.
obuense (IMM-101 ) and the disorder is characterised by the presence of one or more of the following tumour associate antigens:
ERB2, CDK4, RASK, WTIP, CDC27, MAGEA1 , MUC5AC, TP53, or CSAG2.
17. A non-viable Mycobacterium for therapeutic use in priming dendritic cells in a patient suffering a neoplastic disorder, wherein the Mycobacterium is M. vaccae and the disorder is characterised by the presence of one or more of the following tumour associated antigens:
CDK4, ERBB2, RASK, PTPRC, GAGE7, MUC5A, GAGE2b, TP53,
GAGE2a, CDC27, MSLN, MAGEA1 , MUC16, REC04, or SSX2.
18. A method for treating a neoplastic disorder in a patient, comprising administering to the patient a non-viable whole cell Mycobacterium and one or more tumour associated antigens (TAA), wherein the disorder is characterised by the presence of said one or more antigens, and wherein the antigen(s) to be administered to the patient have genetic homology to sequences in said Mycobacterium.
19. A method according to claim 18, wherein the Mycobacterium is M. obuense (IMM-101 ) and said antigen(s) is selected from:
ERB2, CDK4, RASK, WTIP, CDC27, MAGEA1 , MUC5AC, TP53, or CSAG2.
20. A method according to claim 18, wherein the Mycobacterium is M. vaccae and said antigen(s) is selected from:
CDK4, ERBB2, RASK, PTPRC, GAGE7, MUC5A, GAGE2b, TP53, GAGE2a, CDC27, MSLN, MAGEA1 , MUC16, REC04, or SSX2.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1601248.6A GB201601248D0 (en) | 2016-01-22 | 2016-01-22 | Cancer therapy |
GB1601248.6 | 2016-01-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017125765A1 true WO2017125765A1 (en) | 2017-07-27 |
Family
ID=55534813
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2017/050164 WO2017125765A1 (en) | 2016-01-22 | 2017-01-23 | Immunotherapeutic treatment of cancer |
Country Status (2)
Country | Link |
---|---|
GB (1) | GB201601248D0 (en) |
WO (1) | WO2017125765A1 (en) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110243992A1 (en) * | 2008-08-29 | 2011-10-06 | Vanderbilt University | Methods of enhancing the immunogenicity of mycobacteria and compositions for the treatment of cancer, tuberculosis, and fibrosing lung diseases |
WO2013083659A1 (en) * | 2011-12-05 | 2013-06-13 | Cambridge Enterprise Limited | Combination treatment comprising ho - 1 inhibitor and immunotherapeutic agent |
WO2014181121A1 (en) * | 2013-05-09 | 2014-11-13 | Immodulon Therapeutics | Cancer therapy |
WO2015092382A1 (en) * | 2013-12-20 | 2015-06-25 | Immodulon Therapeutics Limited | A checkpoint inhibitor and a whole cell mycobacterium for use in cancer therapy |
-
2016
- 2016-01-22 GB GBGB1601248.6A patent/GB201601248D0/en not_active Ceased
-
2017
- 2017-01-23 WO PCT/GB2017/050164 patent/WO2017125765A1/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110243992A1 (en) * | 2008-08-29 | 2011-10-06 | Vanderbilt University | Methods of enhancing the immunogenicity of mycobacteria and compositions for the treatment of cancer, tuberculosis, and fibrosing lung diseases |
WO2013083659A1 (en) * | 2011-12-05 | 2013-06-13 | Cambridge Enterprise Limited | Combination treatment comprising ho - 1 inhibitor and immunotherapeutic agent |
WO2014181121A1 (en) * | 2013-05-09 | 2014-11-13 | Immodulon Therapeutics | Cancer therapy |
WO2015092382A1 (en) * | 2013-12-20 | 2015-06-25 | Immodulon Therapeutics Limited | A checkpoint inhibitor and a whole cell mycobacterium for use in cancer therapy |
Non-Patent Citations (33)
Title |
---|
"Remington's Pharmaceutical Sciences, 18th ed.", 1990, MACK PRINTING COMPANY |
"Remington's Pharmaceutical Sciences, 18th ed.", 1990, MACK PRINTING COMPANY, pages: 1289 - 1329 |
AI-KURAYA K; NOVOTNY H; BAVI P ET AL.: "HER2, TOP2A, CCND1, EGFR and C-MYC oncogene amplification in colorectal cancer", J. CLIN. PATHOL, vol. 60, 2007, pages 768 |
ALTIRRIBA J; GARCIA A; SANCHEZ B ET AL.: "The sole presence of CDK4 is not a solid criterion for discriminating between tumor and healthy pancreatic tissues", INT. J. CANCER., vol. 130, 2012, pages 2743 |
AN HX.: "Gene amplification and overexpression of CDK4 in sporadic breast carcinomas is associated with high tumor cell proliferation.", AM. J. PATHOL., vol. 154, 1999, pages 113 |
ANDERSON BW; PEOPLES GE; MURRAY JL ET AL.: "Peptide priming of cytolytic activity to HER-2 epitope 369-377 in healthy individuals", CLIN. CANCER RES., vol. 6, 2000, pages 4192 |
AZUMA K; SHICHIJO S; SHOMURA H ET AL.: "Identification of HER2/ neu-derived peptides capable of inducing both cellular and humoral immune responses in HLA-A24 positive breast cancer patients.", BREAST CANCER RES. TREAT., vol. 86, 2004, pages 19, XP055021083, DOI: doi:10.1023/B:BREA.0000032920.95410.63 |
BEARD RE; ABATE-DAGA D; ROSATI SF ET AL.: "Gene expression profiling using nanostring digital RNA counting to identify potential target antigens for melanoma immunotherapy.", CLIN. CANCER RES., vol. 19, 2013, pages 4941 |
CHIKAMATSU K; ALBERS A; STANSON J ET AL.: "p53-specific human CD4+ T-helper cells enhance in vitro generation and antitumor function of tumor-reactive CD8+ T cells.", CANCER RES., vol. 63, 2003, pages 3675 |
DAUDI S; ENG KH; MHAWECH-FAUCEGLIA P ET AL.: "Expression and immune responses to MAGE antigens predict survival in epithelial ovarian cancer", PLOS ONE., vol. 9, 2014, pages E104099 |
GJERTSEN MK; BJORHEIM J; SAETERDAL I; MYKLEBUST J; GAUDERNACK G.: "Cytotoxic CD4+ and CD8+ T lymphocytes, generated by mutant p21-ras (12Val) peptide vaccination of a patient, recognize 12Val-dependent nested epitopes present within the vaccine peptide and kill autologous tumour cells carrying this mutation", INT. J. CANCER., vol. 72, 1997, pages 784, XP055111365, DOI: doi:10.1002/(SICI)1097-0215(19970904)72:5<784::AID-IJC14>3.0.CO;2-9 |
HOUBIERS JGA; NIJMAN HW; VAN DER BURG SH ET AL.: "In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53.", EUR. J. IMMUNOL., vol. 23, 1993, pages 2072, XP002928271, DOI: doi:10.1002/eji.1830230905 |
JANJIC B; ANDRADE P; WANG X-F ET AL.: "Spontaneous CD4+ T Cell Responses against TRAG-3 in Patients with Melanoma and Breast Cancers.", J. IMMUNOL., vol. 177, 2006, pages 2717 |
KAPLAN BL; NORELL H; CALLENDER GG ET AL.: "Interferon-gamma renders tumors that express low levels of Her-2/neu sensitive to cytotoxic T cells.", CANCER IMMUNOL. IMMUNOTHER., vol. 55, 2006, pages 653, XP019333245, DOI: doi:10.1007/s00262-005-0050-5 |
KARAM JA; HUANG S; FAN J ET AL.: "Upregulation of TRAG3 gene in urothelial carcinoma of the bladder", INT. J. CANCER, vol. 128, 2011, pages 2823 |
KIM GE; BAE HI; PARK HU ET AL.: "Aberrant expression of MUC5AC and MUC6 gastric mucins and sialyl Tn antigen in intraepithelial neoplasms of the pancreas", GASTROENTEROLOGY, vol. 123, 2002, pages 1052 |
L. BUONAGURO ET AL: "Translating Tumor Antigens into Cancer Vaccines", CLINICAL AND VACCINE IMMUNOLOGY, vol. 18, no. 1, 3 November 2010 (2010-11-03), pages 23 - 34, XP055085864, ISSN: 1556-6811, DOI: 10.1128/CVI.00286-10 * |
LOLLINI PL; NICOLETTI G; LANDUZZI L ET AL.: "Down regulation of major histocompatibility complex class I expression in mammary carcinoma of HER-2/neu transgenic mice.", INT. J. CANCER, vol. 77, 1998, pages 937 |
MEEK DW; MARCAR L.: "MAGE-A antigens as targets in tumour therapy.", CANCER LETT., vol. 324, 2012, pages 126 |
MIMURA K; KONO K; HANAWA M ET AL.: "Frequencies of HER-2/neu expression and gene amplification in patients with oesophageal squamous cell carcinoma", BR. J. CANCER., vol. 92, 2005, pages 1253 |
MORSE M; DIAZ LA; AZAD NS ET AL.: "A phase Ib/lla study of NEO-102: A therapeutic antibody to treat pancreatic and colorectal cancers.", J. CLIN. ONCOL., vol. 30, 2012, pages 233 |
NAPOLETANO C; RUGHETTI A; LANDI R ET AL.: "Immunogenicity of allo-vesicle carrying ERBB2 tumor antigen for dendritic cell-based anti-tumor immunotherapy", INT J IMMUNOPATHOL PHARMACOL., vol. 22, 2009, pages 647 |
PATEL SP; MORSE M; SHAALAN BEG M ET AL.: "A Phase Ib/lla Study of NEO-102: A Therapeutic Antibody to Treat Pancreatic and Colorectal Cancers (Abstract #243).", J. CLIN. ONCOL, vol. . 32, 2014, pages 243 |
ROULOIS D; GREGOIRE M; FONTENEAU J-F: "MUC1-Specific Cytotoxic T Lymphocytes in Cancer Therapy: Induction and Challenge.", BIOMED RES INT., vol. 871, 2013, pages 936 |
RUIZ R; HUNIS B; RAEZ LE.: "Immunotherapeutic agents in non-small-cell lung cancer finally coming to the front lines.", CURR. ONCOL. REP., vol. 16, 2014, pages 400 |
SELIGER B; RONGCUN Y; ATKINS D ET AL.: "HER-2/neu is expressed in human renal cell carcinoma at heterogeneous levels independently of tumor grading and staging and can be recognized by HLA-A2.1-restricted cytotoxic T lymphocytes.", INT. J. CANCER., vol. 87, 2000, pages 349, XP002377973, DOI: doi:10.1002/1097-0215(20000801)87:3<349::AID-IJC7>3.0.CO;2-O |
TAKAHASHI S; SHIRAISHI T; MILES N ET AL.: "Nanowire Analysis of Cancer-Testis Antigens as Biomarkers of Aggressive Prostate Cancer.", UROLOGY., vol. 85, 2015, pages 704 |
VAN DRIESSCHE A; BERNEMAN ZN; VAN TENDELOO VF.: "Active specific immunotherapy targeting the Wilms' tumor protein 1 (WT1) for patients with hematological malignancies and solid tumors: lessons from early clinical trials", ONCOLOGIST, vol. 17, 2012, pages 250 |
VIERBOOM MPM; NIJMAN HW; OFFRINGA R. ET AL.: "Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes", J. EXP. MED., vol. 186, 1997, pages 695, XP002141232, DOI: doi:10.1084/jem.186.5.695 |
WANG RF; WANG X; ATWOOD AC; TOPALLAN SL; ROSENBERG SA.: "Cloning genes encoding MHC class II-restricted antigens: mutated CDC27 as a tumor antigen.", SCIENCE, vol. 284, 1999, pages 1351 |
WEON JL; POTTS PR.: "The MAGE protein family and cancer", CURR. OP. CELL BIO., vol. 37, 2015, pages 1, XP029343219, DOI: doi:10.1016/j.ceb.2015.08.002 |
WOLFEL T; HAUER M; SCHNEIDER J ET AL.: "A p16lNK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma", SCIENCE, vol. 269, 1995, pages 1281, XP001093623, DOI: doi:10.1126/science.7652577 |
YAMAZOE S; TANAKA H; SAWADA, T ET AL.: "RNA interference suppression of mucin 5AC (MUC5AC) reduces the adhesive and invasive capacity of human pancreatic cancer cells", J. EXP. CLIN. CANCER RES., vol. 29, 2010, pages 53, XP021083460, DOI: doi:10.1186/1756-9966-29-53 |
Also Published As
Publication number | Publication date |
---|---|
GB201601248D0 (en) | 2016-03-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Rodríguez-Cerdeira et al. | Advances in immunotherapy for melanoma: a comprehensive review | |
US11369668B1 (en) | Tumor cell vaccines | |
Yu et al. | Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors | |
EP3784255A1 (en) | T cell receptors with mage-b2 specificity and uses thereof | |
US20240093200A1 (en) | Compositions and methods for improving immune system function | |
US20140120136A1 (en) | Mir-155 enhancement of cd8+ t cell immunity | |
US9675633B2 (en) | miRNA for treating cancer and for use with adoptive immunotherapies | |
Liu et al. | Integrated nanovaccine with microRNA-148a inhibition reprograms tumor-associated dendritic cells by modulating miR-148a/DNMT1/SOCS1 axis | |
WO2021136933A1 (en) | Immunotherapeutic treatment of cancer | |
Chen et al. | Epigenetics regulates antitumor immunity in melanoma | |
US9795660B2 (en) | Id-protein targeted tumor cell vaccine | |
Mahiddine et al. | CD99 isoforms regulate CD1a expression in human monocyte‐derived DCs through ATF‐2/CREB‐1 phosphorylation | |
AU2016355586A1 (en) | Compositions and methods of treating cancer | |
US20220354904A1 (en) | Cancer therapy | |
US20230000963A1 (en) | Tumor cell vaccines | |
WO2017125765A1 (en) | Immunotherapeutic treatment of cancer | |
WO2023055885A2 (en) | Ezh2 inhibition in pancreatic cancer | |
Sanaei et al. | Lung cancer vaccination from concept to reality: A critical review of clinical trials and latest advances | |
US8133875B2 (en) | Method for inhibiting scavenger receptor-A and increasing immune response to antigens | |
Sun et al. | Demethylation of cancer/testis antigens and CpG ODN stimulation enhance dendritic cell and cytotoxic T lymphocyte function in a mouse mammary model | |
Zhang et al. | Zebularine potentiates anti-tumor immunity by inducing tumor immunogenicity and improving antigen processing through cGAS-STING pathway | |
WO2020214820A2 (en) | Aim2 inhibitors and uses thereof | |
Dai | An escherichia coli vaccine co-expressing listeriolysin-O and tumour antigen in cancer immunotherapy and the mechanisms of immune regulation | |
BR102020024609A2 (en) | INTERFERENCE RNA COMPOUNDS FOR TRANSCRIPTIONAL INHIBITION OF FOXP3 METHODS OF OBTAINING THEM, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USE | |
WO2020092140A2 (en) | Methods and compositions to induce or suppress immune responses through the use of membrane bound complement split products |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17702685 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 17702685 Country of ref document: EP Kind code of ref document: A1 |